UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
☒ QUARTERLY REPORT PURSUANT TO SECTION
13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2024
or
☐ TRANSITION REPORT PURSUANT TO SECTION
13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from __________ to
__________
Commission file number: 001-41518
Qomolangma Acquisition Corp. |
(Exact name of registrant as specified in its charter) |
Delaware | | 86-3733656 |
(State or other jurisdiction of
incorporation or organization) | | (I.R.S. Employer
Identification No.) |
1178 Broadway, 3rd Floor New York, NY 10010 |
(Address of principal executive offices) |
(646) 791-7587 |
(Registrant’s telephone number, including area code) |
|
(Former name, former address and former fiscal year, if changed since last report) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | | Trading Symbol(s) | | Name of each exchange
on which registered |
Units | | QOMOU | | The Nasdaq Stock Market LLC |
Common Stock | | QOMO | | The Nasdaq Stock Market LLC |
Warrants | | QOMOW | | The Nasdaq Stock Market LLC |
Rights | | QOMOR | | The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant
(1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months
(or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements
for the past 90 days. Yes ☐ No ☒
Indicate by check mark whether the registrant
has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405
of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes
☒ No ☐
Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.
See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,”
and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer | ☐ | Accelerated filer | ☐ | |
Non-accelerated filer | ☒ | Smaller reporting company | ☒ | |
| | Emerging growth company | ☒ | |
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant
is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☒ No ☐
As of July 25, 2024, there were 2,500,480 shares
of the registrant’s common stock, $0.0001 par value, issued and outstanding.
QOMOLANGMA ACQUISITION CORP.
FORM 10-Q
FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2024
TABLE OF CONTENTS
Part
I – Financial Information
Item 1. Financial Statements.
QOMOLANGMA ACQUISITION CORP.
CONDENSED BALANCE SHEETS
| |
March 31, 2024 (Unaudited) | | |
December 31, 2023 (Audited) | |
Assets | |
| | |
| |
Current Assets | |
| | |
| |
Cash | |
$ | 6,309 | | |
$ | 9,222 | |
Prepaid expenses | |
| 34,891 | | |
| 69,781 | |
Total Current Assets | |
| 41,200 | | |
| 79,003 | |
Investments held in Trust Account | |
| 9,440,722 | | |
| 9,299,336 | |
Total Assets | |
$ | 9,481,922 | | |
$ | 9,378,339 | |
| |
| | | |
| | |
Liabilities, Temporary Equity, and Stockholders’ Deficit | |
| | | |
| | |
Current Liabilities | |
| | | |
| | |
Accounts payable and accrued expenses | |
$ | 841,491 | | |
$ | 829,931 | |
Accrued expenses – related party | |
| 178,387 | | |
| 148,387 | |
Due to related party | |
| 100,494 | | |
| 65,726 | |
Franchise tax payable | |
| 30,500 | | |
| 24,400 | |
Income tax payable | |
| 465,475 | | |
| 434,300 | |
Excise tax liability | |
| 469,218 | | |
| 469,218 | |
Promissory note - related party | |
| 937,252 | | |
| 937,252 | |
Total Current Liabilities | |
| 3,022,817 | | |
| 2,909,214 | |
| |
| | | |
| | |
Deferred tax liability | |
| 8,719 | | |
| 15,684 | |
Deferred underwriting fee payable | |
| 2,109,200 | | |
| 2,109,200 | |
Total Liabilities | |
| 5,140,736 | | |
| 5,034,098 | |
| |
| | | |
| | |
Commitments and Contingencies | |
| | | |
| | |
| |
| | | |
| | |
Common stock subject to possible redemption, $0.0001 par value; 16,000,000 shares authorized; 837,857 shares issued and outstanding at redemption value of $10.67 and $10.54 at March 31, 2024 and December 31, 2023, respectively | |
| 8,938,530 | | |
| 8,827,454 | |
| |
| | | |
| | |
Stockholders’ Deficit | |
| | | |
| | |
Common stock, $0.0001 par value; 16,000,000 shares authorized; 1,662,623 shares issued and outstanding (excluding 837,857 shares subject to possible redemption) | |
| 166 | | |
| 166 | |
Accumulated deficit | |
| (4,597,510 | ) | |
| (4,483,379 | ) |
Total Stockholders’ Deficit | |
| (4,597,344 | ) | |
| (4,483,213 | ) |
Total Liabilities, Temporary Equity, and Stockholders’ Deficit | |
$ | 9,481,922 | | |
$ | 9,378,339 | |
The accompanying notes are an integral part of
these unaudited condensed financial statements.
QOMOLANGMA ACQUISITION CORP.
UNAUDITED CONDENSED STATEMENTS OF OPERATIONS
| |
Three Months Ended March 31, | |
| |
2024 | | |
2023 | |
| |
| | |
| |
General and administrative expenses | |
$ | 94,131 | | |
$ | 666,320 | |
Franchise tax expenses | |
| 6,100 | | |
| 12,700 | |
Loss from operations | |
| (100,231 | ) | |
| (679,020 | ) |
| |
| | | |
| | |
Interest earned on investments held in Trust Account | |
| 121,386 | | |
| 572,382 | |
Income (loss) before income taxes | |
| 21,155 | | |
| (106,638 | ) |
| |
| | | |
| | |
Income tax provision | |
| (24,210 | ) | |
| (117,533 | ) |
Net loss | |
$ | (3,055 | ) | |
$ | (224,171 | ) |
| |
| | | |
| | |
Basic and diluted weighted average shares outstanding, redeemable common stock | |
| 837,857 | | |
| 5,273,000 | |
| |
| | | |
| | |
Basic and diluted net income per share, redeemable common stock | |
| 0.09 | | |
| 0.14 | |
| |
| | | |
| | |
Basic and diluted weighted average shares outstanding, non-redeemable common stock | |
| 1,662,623 | | |
| 1,662,623 | |
| |
| | | |
| | |
Basic and diluted net loss per share, non-redeemable common stock | |
$ | (0.05 | ) | |
$ | (0.58 | ) |
The accompanying notes are an integral part of
these unaudited condensed financial statements.
QOMOLANGMA ACQUISITION CORP.
UNAUDITED CONDENSED STATEMENTS OF CHANGES IN
STOCKHOLDERS’ EQUITY (DEFICIT)
For the Three Months Ended March 31, 2024
| |
Common stock | | |
Accumulated | | |
Total Stockholders’ | |
| |
Shares | | |
Amount | | |
Deficit | | |
Deficit | |
Balance as of January 1, 2024 | |
| 1,662,623 | | |
$ | 166 | | |
$ | (4,483,379 | ) | |
$ | (4,483,213 | ) |
Accretion of redeemable common stock to redemption value | |
| — | | |
| — | | |
| (111,076 | ) | |
| (111,076 | ) |
Net loss | |
| — | | |
| — | | |
| (3,055 | ) | |
| (3,055 | ) |
Balance as of March 31, 2024 | |
| 1,662,623 | | |
$ | 166 | | |
$ | (4,597,510 | ) | |
$ | (4,597,344 | ) |
For the Three Months Ended March 31, 2023
| |
Common stock | | |
Additional Paid-in | | |
Retained Earnings (Accumulated | | |
Total Stockholders’ | |
| |
Shares | | |
Amount | | |
Capital | | |
Deficit) | | |
Equity | |
Balance as of January 1, 2023 | |
| 1,662,623 | | |
$ | 166 | | |
$ | 4,914,221 | | |
$ | 130,916 | | |
$ | 5,045,303 | |
Accretion of redeemable common stock to redemption value | |
| — | | |
| — | | |
| (3,802,141 | ) | |
| — | | |
| (3,802,141 | ) |
Net loss | |
| — | | |
| — | | |
| — | | |
| (224,171 | ) | |
| (224,171 | ) |
Balance as of March 31, 2023 | |
| 1,662,623 | | |
$ | 166 | | |
$ | 1,112,080 | | |
$ | (93,255 | ) | |
$ | 1,018,991 | |
The accompanying notes are an integral part of these unaudited condensed
financial statements.
QOMOLANGMA ACQUISITION CORP.
UNAUDITED CONDENSED STATEMENTS OF CASH FLOWS
| |
Three
Months Ended March 31, | |
| |
2024 | | |
2023 | |
Cash
flows from operating activities: | |
| | |
| |
Net
loss | |
$ | (3,055 | ) | |
$ | (224,171 | ) |
Adjustments
to reconcile net cash used in operating activities: | |
| | | |
| | |
Interest
earned on investments held in Trust Account | |
| (121,386 | ) | |
| (572,382 | ) |
Deferred
income tax | |
| (6,965 | ) | |
| 7,232 | |
Changes
in current assets and current liabilities: | |
| | | |
| | |
Prepaid
expenses | |
| 34,890 | | |
| 2,180 | |
Accounts
payable and accrued expenses | |
| 26,328 | | |
| 435,406 | |
Accrued
expenses – related party | |
| 30,000 | | |
| — | |
Franchise
tax payable | |
| 6,100 | | |
| (32,728 | ) |
Income
tax payable | |
| 31,175 | | |
| 110,301 | |
Net
cash used in operating activities | |
| (2,913 | ) | |
| (274,162 | ) |
| |
| | | |
| | |
Cash
Flows from Investing Activities: | |
| | | |
| | |
Cash
withdrawal from Trust Account to pay franchise tax | |
| — | | |
| 45,429 | |
Net
cash provided by investing activities | |
| — | | |
| 45,429 | |
| |
| | | |
| | |
Cash
Flows from Financing Activities: | |
| | | |
| | |
Proceeds
from issuance of promissory note to related party | |
| — | | |
| 200,000 | |
Net
cash provided by financing activities | |
| — | | |
| 200,000 | |
| |
| | | |
| | |
Net
change in cash | |
| (2,913 | ) | |
| (28,733 | ) |
Cash,
beginning of the period | |
| 9,222 | | |
| 196,510 | |
Cash,
end of the period | |
$ | 6,309 | | |
$ | 167,777 | |
| |
| | | |
| | |
Supplemental
Disclosure of Non-cash Investing and Financing Activities | |
| | | |
| | |
Extension
fees paid by the Sponsor through Due to related party | |
$ | 20,000 | | |
$ | — | |
Accrued
expenses paid by the Sponsor through Due to related party | |
$ | 14,768 | | |
$ | — | |
Accretion
of Common stock to redemption value | |
$ | 111,076 | | |
$ | 3,802,141 | |
The accompanying notes are an integral part of
these unaudited condensed financial statements.
QOMOLANGMA ACQUISITION CORP.
NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS
Note 1 — Description of Organization and Business Operations
Qomolangma Acquisition Corp. (the “Company”)
is a blank check company incorporated as a Delaware corporation on May 6, 2021. The Company was formed for the purpose of effecting
a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses
or entities (“Business Combination”). The Company intends to pursue target businesses that are strategically significant in
the Asian markets and focus on businesses with a total enterprise value of between $300,000,000 and $500,000,000.
As of March 31, 2024, the Company had not commenced
any operations. All activities through March 31, 2024 are related to the Company’s formation and the proposed initial public offering
(“IPO” as defined below) and, subsequent to the IPO, identifying a target company for a Business Combination. The Company
will not generate any operating revenues until after the completion of a Business Combination, at the earliest. The Company generates
non-operating income in the form of interest income from the proceeds derived from the IPO. The Company has selected December 31
as its fiscal year end.
The Company’s sponsor is Qomolangma Investments
LLC (the “Sponsor”), a Delaware limited liability company.
The registration statement for the Company’s
IPO became effective on September 29, 2022. On October 4, 2022, the Company consummated the IPO of 5,000,000 units at an offering price
of $10.00 per unit (the “Public Units’), generating gross proceeds of $50,000,000. Simultaneously with the closing of the
IPO, the Company sold to the Sponsor, in a private placement, 260,500 units, at $10.00 per unit (the “Private Units”), generating
total gross proceeds of $2,605,000.
Transaction costs from the IPO amounted to $4,222,030,
consisting of $875,000 of underwriting fees, $2,000,000 of deferred underwriting fees (payable only upon completion of a Business Combination)
and $1,347,030 of other offering costs.
The Company granted the underwriter a 45-day option
to purchase up to 750,000 additional Public Units to cover over-allotments, if any. On October 4, 2022, the underwriter partially exercised
the over-allotment option and purchased 273,000 Public Units at a price of $10.00 per Public Unit on October 7, 2022, generating gross
proceeds of $2,730,000. Simultaneously with the closing of the over-allotment option, the Company consummated the private placement of
an additional 8,873 Private Units generating gross proceeds of $88,725.
A total of $53,520,950 ($10.15 per Unit) of the
net proceeds from the sale of Units in the IPO (including the Over-Allotment Option Units) and the private placements on October 4, 2022
and October 7, 2022, was placed in a trust account (the “Trust Account”) maintained by American Stock Transfer & Trust
Company as a trustee and are invested only in U.S. government treasury bills with a maturity of 185 days or less or in money market funds
meeting certain conditions under Rule 2a-7 under the Investment Company Act of 1940, as amended (the “Investment Company Act”),
and that invest only in direct U.S. government treasury obligations. These funds will not be released until the earlier of the completion
of the initial Business Combination and the liquidation due to the Company’s failure to complete a Business Combination within the
applicable period of time. The proceeds deposited in the Trust Account could become subject to the claims of the Company’s creditors,
if any, which could have priority over the claims of the Company’s public stockholders. In addition, interest income earned on investments
held in the Trust Account may be released to the Company to pay its income or other tax obligations. With these exceptions, expenses incurred
by the Company may be paid prior to a Business Combination only from the net proceeds of the IPO and private placement not held in the
Trust Account.
Pursuant to Nasdaq listing rules, the Company’s
initial Business Combination must occur with one or more target businesses having an aggregate fair market value equal to at least 80%
of the value of the funds in the Trust account (excluding any deferred underwriting discounts and commissions and taxes payable on the
income earned on the Trust Account), which the Company refers to as the 80% test, at the time of the execution of a definitive agreement
for its initial Business Combination, although the Company may structure a Business Combination with one or more target businesses whose
fair market value significantly exceeds 80% of the trust account balance. If the Company is no longer listed on Nasdaq, it will not be
required to satisfy the 80% test. The Company will only complete a Business Combination if the post-transaction company owns or acquires
50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for
it not to be required to register as an investment company under the Investment Company Act.
The Company will provide its holders of the outstanding
Public Shares (the “Public Stockholders”) with the opportunity to redeem all or a portion of their Public Shares upon the
completion of a Business Combination either (i) in connection with a stockholder meeting called to approve the Business Combination or
(ii) by means of a tender offer. The decision as to whether the Company will seek stockholder approval of a Business Combination or conduct
a tender offer will be made by the Company, solely in its discretion. The Public Stockholders will be entitled to redeem their Public
Shares for a pro rata portion of the amount then in the Trust Account (initially anticipated to be $10.15 per Public Share, plus any pro
rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its franchise and income
tax obligations).
The Company will proceed with a Business Combination
if the Company has net tangible assets of at least $5,000,001 upon such consummation of a Business Combination and, if the Company seeks
stockholder approval, a majority of the shares of common stock voted are voted in favor of the Business Combination. If a stockholder
vote is not required by law and the Company does not decide to hold a stockholder vote for business or other legal reasons, the Company
will, pursuant to its Amended and Restated Certificate of Incorporation (the “Amended and Restated Certificate of Incorporation”),
conduct the redemptions pursuant to the tender offer rules of the U.S. Securities and Exchange Commission (“SEC”) and
file tender offer documents with the SEC prior to completing a Business Combination. If, however, stockholder approval of the transaction
is required by law, or the Company decides to obtain stockholder approval for business or legal reasons, the Company will offer to redeem
shares in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules. Additionally,
each Public Stockholder may elect to redeem their Public Shares irrespective of whether they vote for or against the proposed transaction.
If the Company seeks stockholder approval in connection with a Business Combination, the Company’s Sponsor and any of the Company’s
officers or directors that may hold Founder Shares (as defined in Note 5) (the “Initial Stockholders”) and the underwriters
have agreed (a) to vote their Founder Shares, Private Shares (as defined in Note 4), and any Public Shares purchased during
or after the IPO in favor of approving a Business Combination and (b) not to convert any shares (including the Founder Shares) in
connection with a stockholder vote to approve, or sell the shares to the Company in any tender offer in connection with, a proposed Business
Combination.
The Initial Stockholders have agreed (a) to
waive their redemption rights with respect to the Founder Shares, Private Shares, and Public Shares held by them in connection with the
completion of a Business Combination and (b) not to propose, or vote in favor of, an amendment to the Amended and Restated Certificate
of Incorporation that would affect the substance or timing of the Company’s obligation to redeem 100% of its Public Shares if the
Company does not complete a Business Combination, unless the Company provides the Public Stockholders with the opportunity to redeem their
Public Shares in conjunction with any such amendment.
Initially, the Company had until July 4, 2023
(or up to July 4, 2024 if the time to complete a business combination is extended as described herein) to consummate a Business Combination.
In addition, if the Company anticipated that it would not be able to consummate a Business Combination within 9 months, the Company was
able to extend the period of time to consummate a Business Combination up to twelve times, each by an additional one month (for a total
of 21 months to complete a Business Combination). In order to extend the time available for the Company to consummate a Business Combination,
the Company’s insiders or their affiliates or designees, upon five days’ advance notice prior to the applicable deadline,
was required to deposit into the Trust Account $174,009 ($0.033 per Public Share per month), on or prior to the date of the applicable
deadline, for each extension.
On June 29, 2023, the Company held a special meeting
of stockholders (the “June Special Meeting”). At the June Special Meeting, the stockholders amended the Company’s Amended
and Restated Certificate of Incorporation to allow the Company to consummate a business combination until August 4, 2023 (or up to August
4, 2024 if the time to complete a business combination is extended as described herein) to consummate a Business Combination. In addition,
if the Company anticipates that it may not be able to consummate a Business Combination by August 4, 2023, the Company may extend the
period of time to consummate a Business Combination up to twelve times, each by an additional one month (for a total of 22 months to complete
a Business Combination) (the “Combination Period”). In order to extend the time available for the Company to consummate a
Business Combination, the Company’s insiders or their affiliates or designees, upon five days’ advance notice prior to the
applicable deadline, must deposit into the Trust Account the lesser of $0.033 per outstanding share and $80,000 per month, on or prior
to the date of the applicable deadline, for each extension.
In connection with the June Special Meeting, an
aggregate of 2,126,934 shares with redemption value of approximately $22,141,383 (or $10.41 per share) of the Company’s common stock
were tendered for redemption.
On June 29, 2023, the Sponsor made a deposit of
$240,000 to the Trust Account and extended the period of time the Company has to consummate an initial Business Combination from July
4, 2023 to October 4, 2023.
On September 12, 2023, the Company held a special
meeting of stockholders (the “September Special Meeting”). At the Special Meeting, the stockholders amended the Company’s
Amended and Restated Certificate of Incorporation to allow the Company to undertake an initial business combination with an entity or
business, with a physical presence, operation, or other significant ties to China (a “China-based Target”) or which may subject
the post-business combination business to the laws, regulations and policies of China (including Hong Kong and Macao), or entity or business
that conducts operations in China through variable interest entities, or VIEs, pursuant to a series of contractual arrangements with the
VIE and its shareholders on one side, and a China-based subsidiary of the China-based Target, on the other side.
In connection with the September Special Meeting,
an aggregate of 1,233,054 shares with redemption value of approximately $13,082,703 (or $10.61 per share) of the Company’s common
stock were tendered for redemption.
On October 31, 2023 and November 29, 2023, the
Sponsor made a deposit of $63,129 each time into the Trust Account and extended the period of time the Company has to consummate an initial
Business Combination from November 4, 2023 to January 4, 2024.
On December 7, 2023, the Company held a special
meeting of stockholders. At the special meeting, holders of 3,575,635 shares of common stock of the Company were present in person or
by proxy, representing 81.18% of the total shares of common stock as of November 15, 2023, the record date for the special meeting, and
constituting a quorum for the transaction of business. At the special meeting, the stockholders approved further amendments to our amended
and restated certificate of incorporation and Trust Agreement to reduce the amount the Company must deposit into the Trust Account to
extend the date on which the trustee must liquidate the trust account established by the Company in connection with the IPO to the lesser
of $0.033 per outstanding share and $20,000 for each one-month extension.
On November 29, 2023, the Sponsor made a deposit
of $63,129 (which did not reflect a reduction of $38,043 extension fee as a result of the Company’s December 2023 public shares
redemption) into the Trust Account and extended the period of time the Company has to consummate an initial Business Combination from
December 4, 2023 to January 4, 2024.
The Sponsor made a monthly deposit of $20,000
into the Trust Account from December 2023 to July 2024 and extended the period of time the Company has to consummate an initial Business
Combination from January 4, 2024 to August 4, 2024.
If the Company is unable to complete a Business
Combination within the Combination Period, the Company will (i) cease all operations except for the purpose of winding up, (ii) as
promptly as reasonably possible but not more than ten business days thereafter, redeem the Public Shares, at a per-share price,
payable in cash, equal to the aggregate amount then on deposit in the Trust Account including interest (which interest shall be net of
taxes payable, and less certain amount of interest to pay dissolution expenses) divided by the number of then outstanding Public Shares,
which redemption will completely extinguish Public Stockholders’ rights as stockholders (including the right to receive further
liquidating distributions, if any), subject to applicable law, and (iii) as promptly as reasonably possible following such redemption,
subject to the approval of the Company’s remaining stockholders and the Company’s board of directors, dissolve and liquidate,
subject in each case to the Company’s obligations under Delaware law to provide for claims of creditors and the requirements of
other applicable law.
The Initial Stockholders have agreed to waive
their liquidation rights with respect to the Founder Shares and Private Shares if the Company fails to complete a Business Combination
within the Combination Period. However, if the Sponsor or underwriters acquires Public Shares in or after the IPO, such Public Shares
will be entitled to liquidating distributions from the Trust Account if the Company fails to complete a Business Combination within the
Combination Period. The underwriters have agreed to waive their rights to their deferred underwriting commission (see Note 6) held
in the Trust Account in the event the Company does not complete a Business Combination within in the Combination Period and, in such event,
such amounts will be included with the other funds held in the Trust Account that will be available to fund the redemption of the Public
Shares. In the event of such distribution, it is possible that the per share value of the assets remaining available for distribution
will be less than $10.15.
In order to protect the amounts held in the Trust
Account, the Sponsor has agreed to be liable to the Company if and to the extent any claims by a vendor for services rendered or products
sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce
the amount of funds in the Trust Account to below $10.15 per Public Share, except as to any claims by a third party who executed a valid
and enforceable agreement with the Company waiving any right, title, interest or claim of any kind they may have in or to any monies held
in the Trust Account and except as to any claims under the Company’s indemnity of the underwriters of the IPO against certain liabilities,
including liabilities under the Securities Act of 1933, as amended (the “Securities Act”). Moreover, in the event
that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any
liability for such third party claims.
Liquidity, Capital Resources and Going Concern
As of March 31, 2024, the Company had $6,309 of
cash held outside its trust account and a working capital deficit of $2,981,617. On March 22, 2023, June 26, 2023, September 12, 2023,
September 26, 2023 and October 26, 2023, the Sponsor loaned the Company $200,000, $240,000, $150,000, $47,227, and $145,000, respectively,
to be used, in part, for extension deposits. All promissory notes bear no interest and are repayable in full upon the consummation of
the Company’s Business Combination.
As a result of the Sponsor’s deposit of
$63,129 each time to the Trust Account on October 31, 2023 and November 29, 2023 (which did not reflect a reduction of $38,043 extension
fee as a result of the Company’s December 2023 public shares redemption), and the monthly deposit of $20,000 into the Trust Account
from December 2023 to July 2024, the Company has until August 4, 2024 (unless the Company extends the time to complete a Business Combination)
to consummate a Business Combination. It is uncertain that the Company will be able to consummate a Business Combination by this time.
If a Business Combination is not consummated by this date, there will be a mandatory liquidation and subsequent dissolution.
The Company expects to continue to incur significant
professional costs to remain as a publicly traded company and to incur significant transaction costs in pursuit of the consummation of
a Business Combination. The Company may need to obtain additional financing either to complete its Business Combination or because it
becomes obligated to redeem a significant number of public shares upon consummation of its Business Combination, in which case the Company
may issue additional securities or incur debt in connection with such Business Combination. Subject to compliance with applicable securities
laws, the Company would only complete such financing simultaneously with the completion of our Business Combination. If the Company is
unable to complete its Business Combination because it does not have sufficient funds available, it will be forced to cease operations
and liquidate the Trust Account. In addition, following the Business Combination, if cash on hand is insufficient, the Company may need
to obtain additional financing in order to meet its obligations.
In connection with the Company’s assessment
of going concern considerations in accordance with Financial Accounting Standard Board’s Accounting Standards Update (“ASU”)
2014-15, “Disclosures of Uncertainties about an Entity’s Ability to Continue as a Going Concern”, management has determined
that the liquidity and mandatory liquidation conditions raise substantial doubt about the Company’s ability to continue as a going
concern. In addition, if the Company is unable to complete a Business Combination within the Combination Period, the Company’s board
of directors would proceed to commence a voluntary liquidation and thereby a formal dissolution of the Company. There is no assurance
that the Company’s plans to consummate a Business Combination will be successful within the Combination Period. As a result, management
has determined that such additional condition also raise substantial doubt about the Company’s ability to continue as a going concern.
The financial statement does not include any adjustments that might result from the outcome of this uncertainty.
Risks and Uncertainties
In February 2022, an armed conflict escalated
between Russia and Ukraine. The sanctions announced by the United States and other countries against Russia and Belarus following Russia’s
invasion of Ukraine to date include restrictions on selling or importing goods, services, or technology in or from affected regions and
travel bans and asset freezes impacting connected individuals and political, military, business, and financial organizations in Russia
and Belarus. The United States and other countries could impose wider sanctions and take other actions should the conflict further escalate.
Separately, in October 2023, Israel and certain Iranian-backed Palestinian forces began an armed conflict in Israel, the Gaza Strip, and
surrounding areas, which threatens to spread to other Middle Eastern countries including Lebanon and Iran.
As a result of the ongoing Russia/Ukraine, Hamas/Israel
conflicts and/or other future global conflicts, the Company’s ability to consummate a Business Combination, or the operations of
a target business with which the Company ultimately consummates a Business Combination, may be materially and adversely affected. In addition,
the Company’s ability to consummate a transaction may be dependent on the ability to raise equity and debt financing which may be
impacted by these events, including as a result of increased market volatility, or decreased market liquidity in third-party financing
being unavailable on terms acceptable to the Company or at all. The impact of this action and potential future sanctions on the world
economy and the specific impact on the Company’s financial position, results of operations or ability to consummate a Business Combination
are not yet determinable. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.
Inflation Reduction Act of 2022
On August 16, 2022, the Inflation Reduction Act
of 2022 (the “IR Act”) was signed into federal law. The IR Act provides for, among other things, a new U.S. federal 1% excise
tax on certain repurchases (including redemptions) of stock by publicly traded domestic (i.e., U.S.) corporations and certain domestic
subsidiaries of publicly traded foreign corporations. The excise tax is imposed on the repurchasing corporation itself, not its shareholders
from which shares are repurchased. The amount of the excise tax is generally 1% of the fair market value of the shares repurchased at
the time of the repurchase. However, for purposes of calculating the excise tax, repurchasing corporations are permitted to net the fair
market value of certain new stock issuances against the fair market value of stock repurchases during the same taxable year. In addition,
certain exceptions apply to the excise tax. The U.S. Department of the Treasury (the “Treasury”) has been given authority
to provide regulations and other guidance to carry out and prevent the abuse or avoidance of the excise tax. The IR Act applies only to
repurchases that occur after December 31, 2022.
Any redemption or other repurchase that occurs
after December 31, 2022, in connection with a Business Combination, extension vote or otherwise, may be subject to the excise tax. Whether
and to what extent the Company would be subject to the excise tax in connection with a Business Combination, extension vote or otherwise
would depend on a number of factors, including (i) the fair market value of the redemptions and repurchases in connection with the Business
Combination, extension or otherwise, (ii) the structure of a Business Combination, (iii) the nature and amount of any “PIPE”
or other equity issuances in connection with a Business Combination (or otherwise issued not in connection with a Business Combination
but issued within the same taxable year of a Business Combination) and (iv) the content of regulations and other guidance from the Treasury.
In addition, because the excise tax would be payable by the Company and not by the redeeming holder, the mechanics of any required payment
of the excise tax have not been determined. The foregoing could cause a reduction in the cash available on hand to complete a Business
Combination and in the Company’s ability to complete a Business Combination.
As a result of the redemptions by the public stockholders
in June 2023, September 2023, and December 2023, the Company recorded total excise tax liability of $469,218 as of March 31, 2024. The
Company will continue to monitor for updates to the Company’s business along with guidance issued with respect to the IR Act to
determine whether any adjustments are needed to the Company’s tax provision in future periods.
Note 2 — Summary of Significant
Accounting Policies
Basis of Presentation
The accompanying unaudited condensed financial
statements are presented in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”)
and pursuant to the rules and regulations of the SEC. Accordingly, they do not include all of the information and footnotes required by
U.S. GAAP. In the opinion of management, the unaudited condensed financial statements reflect all adjustments, which include only normal
recurring adjustments necessary for the fair statement of the balances and results for the periods presented. The interim results for
the three months ended March 31, 2024 are not necessarily indicative of the results that may be expected through December 31, 2024 or
for any future periods. These financial statements should be read in conjunction with the Company’s 2023 Annual Report on Form 10-K
as filed with the SEC on July 2, 2024.
Emerging Growth Company
The Company is an “emerging growth company,”
as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the
“JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other
public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent
registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations
regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding
advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.
Further, Section 102(b)(1) of the JOBS
Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies
(that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered
under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that
a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies
but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means
that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging
growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison
of the Company’s financial statements with another public company that is neither an emerging growth company nor an emerging growth
company that has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting
standards used.
Use of Estimates
In preparing these unaudited financial statements
in conformity with U.S. GAAP, the Company’s management makes estimates and assumptions that affect the reported amounts of
assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported expenses
during the reporting period.
Making estimates requires management to exercise
significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances
that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near
term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.
Cash and Cash Equivalents
The Company considers all short-term investments
with an original maturity of three months or less when purchased to be cash equivalents. The Company had $6,309 and $9,222 in cash
and none in cash equivalents as of March 31, 2024 and December 31, 2023, respectively.
Investments Held in Trust Account
The Company’s portfolio of investments held
in the Trust Account is comprised of investments in money market funds that invest in U.S. government securities. These securities are
presented on the balance sheet at fair value at the end of each reporting period. Earning on investments held in the Trust Account are
included in interest earned on investments held in Trust Account in the accompanying statements of operations. The estimated fair value
of investments held in the Trust Account is determined using available market information.
Income Taxes
The Company follows the asset and liability method
of accounting for income taxes under ASC 740, “Income Taxes.” Deferred tax assets and liabilities are recognized for
the estimated future tax consequences attributable to differences between the financial statements carrying amounts of existing assets
and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply
to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred
tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation
allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.
The Company’s effective tax rate was 114.44%
and (110.22)% for the three months ended March 31, 2024 and 2023, respectively. The effective tax rate differs from the statutory tax
rate of 21% for the three months ended March 31, 2024 and 2023, due to the valuation allowance on the deferred tax assets.
ASC 740 also clarifies the accounting for uncertainty
in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and a measurement attribute
for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits
to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. ASC 740 also provides
guidance on derecognition, classification, interest and penalties, accounting in interim period, disclosure and transition.
While ASC 740 identifies usage of an effective
annual tax rate for purposes of an interim provision, it does allow for estimating individual elements in the current period if they are
significant, unusual or infrequent. Computing the effective tax rate for the Company is complicated due to the potential impact of the
timing of any Business Combination expenses and the actual interest income that will be recognized during the year. The Company has taken
a position as to the calculation of income tax expense in a current period based on ASC 740-270-25-3 which states, “If an entity
is unable to estimate a part of its ordinary income (or loss) or the related tax (benefit) but is otherwise able to make a reasonable
estimate, the tax (or benefit) applicable to the item that cannot be estimated shall be reported in the interim period in which the item
is reported.” The Company believes its calculation to be a reliable estimate and allows it to properly take into account the usual
elements that can impact its annualized book income and its impact on the effective tax rate. As such, the Company is computing its taxable
income (loss) and associated income tax provision based on actual results for the three months periods ended March 31, 2024 and 2023.
The Company recognizes accrued interest and penalties
related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest
and penalties as of March 31, 2024 and 2023. The Company is currently not aware of any issues under review that could result in significant
payments, accruals or material deviation from its position.
The Company has identified the United States
as its only “major” tax jurisdiction.
The Company may be subject to potential examination
by federal and state taxing authorities in the area of income taxes. These potential examinations may include questioning the timing and
amount of deductions, the nexus of income among various tax jurisdictions and compliance with federal and state tax laws. The Company’s
management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months.
Net Income (Loss) Per Share
The Company complies with accounting and disclosure
requirements of FASB ASC 260, Earnings Per Share. The statements of operations include a presentation of income (loss) per redeemable
share and income (loss) per non-redeemable share following the two-class method of income per share. In order to determine the net income
(loss) attributable to both the redeemable shares and non-redeemable shares, the Company first considered the undistributed income (loss)
allocable to both the redeemable shares and non-redeemable shares and the undistributed income (loss) is calculated using the total net
loss less any dividends paid. The Company then allocated the undistributed income (loss) ratably based on the weighted average number
of shares outstanding between the redeemable and non-redeemable shares. Any remeasurement of the accretion to redemption value of the
common shares subject to possible redemption was considered to be dividends paid to the public shareholders. The 5,542,373 potential shares
of common stock underlying the outstanding Public Warrants and Private Placement Warrants to purchase the Company’s shares of common
stock were excluded from diluted earnings per share for the three months ended March 31, 2024 and 2023 because they are contingently exercisable,
and the contingencies have not yet been met. Additionally, the rights are able to be demanded on or any time after the Business Combination,
and as the contingency has not been met, the rights are excluded from diluted earnings per share for the three months ended March 31,
2024 and 2023. As a result, diluted income (loss) per share is the same as basic income (loss) per share for the periods presented.
The net income (loss) per share presented in the
statements of operations is based on the following:
| |
Three Months Ended March 31, | |
| |
2024 | | |
2023 | |
Net loss | |
$ | (3,055 | ) | |
$ | (224,171 | ) |
Accretion of redeemable common stock to redemption value | |
| (111,076 | ) | |
| (3,802,141 | ) |
Net loss including accretion of redeemable common stock to redemption value | |
$ | (114,131 | ) | |
$ | (4,026,312 | ) |
| |
Three Months Ended March 31, 2024 | | |
Three Months Ended March 31, 2023 | |
| |
Redeemable shares | | |
Non- redeemable shares | | |
Redeemable shares | | |
Non- redeemable shares | |
Basic and diluted net income (loss) per common stock | |
| | |
| | |
| | |
| |
Numerator: | |
| | |
| | |
| | |
| |
Allocation of net loss | |
$ | (38,243 | ) | |
$ | (75,888 | ) | |
$ | (3,061,116 | ) | |
$ | (965,196 | ) |
Accretion of redeemable common stock to redemption value | |
| 111,076 | | |
| — | | |
| 3,802,141 | | |
| — | |
Allocation of net income (loss) | |
$ | 72,833 | | |
$ | (75,888 | ) | |
$ | 741,025 | | |
$ | (965,196 | ) |
| |
| | | |
| | | |
| | | |
| | |
Denominator: | |
| | | |
| | | |
| | | |
| | |
Basic and diluted weighted average shares outstanding | |
| 837,857 | | |
| 1,662,623 | | |
| 5,273,000 | | |
| 1,662,623 | |
Basic and diluted net income (loss) per common stock | |
$ | 0.09 | | |
$ | (0.05 | ) | |
$ | 0.14 | | |
$ | (0.58 | ) |
Concentration of Credit Risk
Financial instruments that potentially subject
the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal
Depository Insurance Coverage of $250,000. As of March 31, 2024 and December 31, 2023, the Company has not experienced losses on these
accounts and management believes the Company is not exposed to significant risks on such accounts.
Fair Value of Financial Instruments
FASB ASC Topic 820 “Fair Value Measurements
and Disclosures” defines fair value, the methods used to measure fair value and the expanded disclosures about fair value measurements.
Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between the
buyer and the seller at the measurement date. In determining fair value, the valuation techniques consistent with the market approach,
income approach and cost approach shall be used to measure fair value. FASB ASC Topic 820 establishes a fair value hierarchy for inputs,
which represent the assumptions used by the buyer and seller in pricing the asset or liability. These inputs are further defined as observable
and unobservable inputs. Observable inputs are those that buyer and seller would use in pricing the asset or liability based on market
data obtained from sources independent of the Company. Unobservable inputs reflect the Company’s assumptions about the inputs that
the buyer and seller would use in pricing the asset or liability developed based on the best information available in the circumstances.
The fair value hierarchy is categorized into three
levels based on the inputs as follows:
| Level
1 | Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to
access. Valuation adjustments and block discounts are not being applied. Since valuations are based on quoted prices that are readily
and regularly available in an active market, valuation of these securities does not entail a significant degree of judgment. |
| Level 2 | Valuations based on (i) quoted prices in active markets for similar assets and liabilities, (ii) quoted prices in markets that
are not active for identical or similar assets, (iii) inputs other than quoted prices for the assets or liabilities, or (iv) inputs that
are derived principally from or corroborated by market through correlation or other means. |
| Level
3 | Valuations based on inputs that are unobservable and significant to the overall fair value measurement. |
The fair value of the Company’s certain
assets and liabilities, which qualify as financial instruments under ASC Topic 820, “Fair Value Measurements and Disclosures,”
approximates the carrying amounts represented in the consolidated balance sheet. The fair values of cash, other current assets, accrued
expenses, and due to sponsor are estimated to approximate the carrying values as of March 31, 2024 and December 31, 2023 due to the short
maturities of such instruments. See Note 8 for the disclosure of the Company’s assets and liabilities that were measured at fair
value on a recurring basis.
Warrants
The Company accounts for warrants as either equity-classified
or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance
in Financial Accounting Standards Board Topic 480, Distinguishing Liabilities from Equity (“ASC 480”) and ASC 815,
Derivatives and Hedging (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments
pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements
for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own ordinary shares and
whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s
control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted
at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. Consequently,
the Company accounts for warrants as equity-classified instruments.
For issued or modified warrants that meet all
of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the
time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required
to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair
value of the warrants are recognized as a non-cash gain or loss on the statements of operations.
Common Stock Subject to Possible Redemption
The Company accounts for its common stock subject
to possible redemption in accordance with the guidance in ASC Topic 480 “Distinguishing Liabilities from Equity.” Common stock
subject to mandatory redemption (if any) are classified as a liability instrument and are measured at fair value. Conditionally redeemable
common stock (including common stock that feature redemption rights that is either within the control of the holder or subject to redemption
upon the occurrence of uncertain events not solely within the Company’s control) is classified as temporary equity. At all other
times, common stock is classified as stockholders’ equity. The Company’s common stock features certain redemption rights that
are considered to be outside of the Company’s control and subject to occurrence of uncertain future events. Accordingly, common
stock subject to possible redemption is presented at redemption value as temporary equity, outside of the stockholders’ equity section
of the Company’s balance sheets.
The Company has made a policy election in accordance with ASC 480-10-S99-3A
and recognizes changes in redemption value in additional paid-in capital or accumulated deficit if additional paid-in capital equals to
zero, over an expected 9-month period leading up to a Business Combination. As of March 31, 2024 and December 31, 2023, the Company recorded
$111,076 and $8,920,393 accretion of redeemable common stock to redemption value, respectively.
At March 31, 2024 and December 31, 2023 and 2022,
the amount of common stock subject to possible redemption reflected in the balance sheets are reconciled in the following table:
Gross proceeds | |
$ | 52,730,000 | |
Less: | |
| | |
Proceeds allocated to public warrants | |
| (3,532,910 | ) |
Proceeds allocated to public rights | |
| (1,845,550 | ) |
Allocation of offering costs related to redeemable shares | |
| (3,932,347 | ) |
Plus: | |
| | |
Accretion of carrying value to redemption value | |
| 3,409,640 | |
Common stock subject to possible redemption - December 31, 2022 | |
$ | 46,828,833 | |
Plus: | |
| | |
Accretion of carrying value to redemption value | |
| 8,920,393 | |
Redemption of public stockholders | |
| (46,921,772 | ) |
Common stock subject to possible redemption - December 31, 2023 | |
$ | 8,827,454 | |
Plus: | |
| | |
Accretion of carrying value to redemption value | |
| 111,076 | |
Common stock subject to possible redemption - March 31, 2024 | |
$ | 8,938,530 | |
Recent Accounting Pronouncements
In August 2020, the Financial Accounting Standards
Board (“FASB”) issued Accounting Standards Update (“ASU”) 2020-06, Debt — Debt with Conversion and Other
Options (Subtopic 470-20) and Derivatives and Hedging — Contracts in Entity’s Own Equity (Subtopic 815-40) (“ASU 2020-06”)
to simplify accounting for certain financial instruments. ASU 2020-06 eliminates the current models that require separation of beneficial
conversion and cash conversion features from convertible instruments and simplifies the derivative scope exception guidance pertaining
to equity classification of contracts in an entity’s own equity. The new standard also introduces additional disclosures for convertible
debt and freestanding instruments that are indexed to and settled in an entity’s own equity. ASU 2020-06 amends the diluted earnings
per share guidance, including the requirement to use the if-converted method for all convertible instruments. ASU 2020-06 is effective
January 1, 2024 for the Company and should be applied on a full or modified retrospective basis, with early adoption permitted beginning
on January 1, 2021. The Company adopted ASU 2020-06 as of January 1, 2024. Adoption of the ASU 2020-06 did not impact the Company’s
financial position, results of operations or cash flows.
In December 2023, the FASB issued Accounting Standards
Update 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosure” (“ASU 2023-09”). ASU 2023-09
mostly requires, on an annual basis, disclosure of specific categories in an entity’s effective tax rate reconciliation and income
taxes paid disaggregated by jurisdiction. The incremental disclosures may be presented on a prospective or retrospective basis. The ASU
is effective for fiscal years beginning after December 15, 2024 with early adoption permitted. The Company is currently assessing the
impact, if any, that ASU 2023-09 would have on its financial position, results of operations or cash flows.
Management does not believe that any recently
issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s financial
statements.
Note 3 — Initial Public Offering
Pursuant to its IPO on October 4, 2022, the Company
sold 5,000,000 Units at a price of $10.00 per Unit, generating gross proceeds of $50,000,000. The Company granted the underwriters a 45-day
option to purchase up to 750,000 additional Public Units to cover over-allotments, if any. On October 7, 2022, the underwriter partially
exercised the over-allotment option and purchased 273,000 Public Units at a price of $10.00 per Public Unit, generating gross proceeds
of $2,730,000. Each Public Unit consists of one share of common stock (“Public Share”), one right (“Public Right”)
and one redeemable warrant (“Public Warrant”). Each Public Right will convert into one-tenth (1/10) of one share of common
stock upon the consummation of a Business Combination. Each Public Warrant entitles the holder to purchase one share of common stock at
a price of $11.50 per share, subject to adjustment. The Public Warrants will become exercisable on the later of 30 days following the
completion of the Company’s initial Business Combination or 12 months from the closing of the IPO, and will expire five years after
the completion of the Company’s initial Business Combination or earlier upon redemption or liquidation.
All of the 5,273,000 Public Shares sold as part
of the Public Units in the IPO (including over-allotment units) contain a redemption feature which allows for the redemption of such Public
Shares if there is a stockholder vote or tender offer in connection with the Business Combination and in connection with certain amendments
to the Company’s amended and restated certificate of incorporation, or in connection with the Company’s liquidation. In accordance
with the SEC and its staff’s guidance on redeemable equity instruments, which has been codified in ASC 480-10-S99, redemption provisions
not solely within the control of the Company require common stock subject to redemption to be classified outside of permanent equity.
The Company’s redeemable common stock is
subject to SEC and its staff’s guidance on redeemable equity instruments, which has been codified in ASC 480-10-S99. If it is probable
that the equity instrument will become redeemable, the Company has the option to either accrete changes in the redemption value over the
period from the date of issuance (or from the date that it becomes probable that the instrument will become redeemable, if later) to the
earliest redemption date of the instrument or to recognize changes in the redemption value immediately as they occur and adjust the carrying
amount of the instrument to equal the redemption value at the end of each reporting period. The Company has made a policy election in
accordance with ASC 480-10-S99-3A and recognizes changes in redemption value in accumulated deficit over an expected 9-month period leading
up to a Business Combination.
Note 4 — Private Placement
Simultaneously with the closing of the IPO, the
Sponsor purchased 260,500 Private Units at a price of $10.00 per Private Unit for an aggregate purchase price of $2,605,000 in a private
placement. Simultaneously with the closing of the over-allotment option, the Company consummated the sale of an additional 8,873 Private
Units with the Sponsor at a price of $10.00 per Private Unit, generating total proceeds of $88,725. Each Private Unit consists of one
share of common stock (“Private Share”), one right (“Private Right”) and one redeemable warrant (“Private
Warrant”). Each Private Right will convert into one-tenth (1/10) of one share of common stock upon the consummation of a Business
Combination. Each Private Warrant entitles the holder to purchase one share of common stock at a price of $11.50 per share, subject to
adjustment. The Private Warrants will be identical to the Public Warrants except that the Private Warrants and the shares of common stock
issuable upon the exercise of the Private Warrants will not be transferable, assignable or salable until after the completion of a Business
Combination. The net proceeds from the Private Units were added to the proceeds from the IPO to be held in the Trust Account. If the Company
does not complete a Business Combination within the Combination Period, the proceeds from the sale of the Private Units will be used to
fund the redemption of the Public Shares (subject to the requirements of applicable law), and the Private Units and all underlying securities
will expire worthless.
Note 5 — Related Party Transactions
Founder Shares
On September 25, 2021, the Company issued
1,437,500 shares of common stock to the Initial Stockholders (the “Founder Shares”) for an aggregated consideration of $25,000,
or approximately $0.017 per share.
The Initial Shareholders have agreed to forfeit
up to 187,500 Founder Shares to the extent that the underwriters’ over-allotment is not exercised in full, so that the Initial Stockholders
will collectively own 20% of the Company’s issued and outstanding shares after the IPO (assuming the Initial Stockholders do not
purchase any Public Shares in the IPO and excluding the Private Units). As a result of the underwriter’s partial exercise of the
over-allotment option on October 4, 2022, 119,250 shares of the Founder Shares were forfeited for no consideration on October 7, 2022
resulting in 1,318,250 Founder Shares outstanding after the forfeiture.
The Initial Stockholders have agreed, subject
to certain limited exceptions, not to transfer, assign or sell any of their Founder Shares until, with respect to 50% of the Founder Shares,
the earlier of six months after the consummation of a Business Combination and the date on which the closing price of the common
stock equals or exceeds $12.50 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like)
for any 20 trading days within a 30-trading day period commencing after a Business Combination and, with respect to the
remaining 50% of the Founder Shares, until the six months after the consummation of a Business Combination, or earlier, in either
case, if, subsequent to a Business Combination, the Company completes a liquidation, merger, stock exchange or other similar transaction
which results in all of the Company’s stockholders having the right to exchange their shares of common stock for cash, securities
or other property.
Due to Related Party
The Company received additional funds from
the Sponsor to finance term extension fees and working capital needs. As of March 31, 2024 and December 31, 2023, the amount due to
related party was $100,494 and $65,726, respectively.
Promissory Note — Related Party
The Company received $155,025 from the Sponsor
at the closing of IPO to finance transaction costs in connection with searching for a target business. On October 7, 2022, the Sponsor
converted the outstanding balance of $155,025 to a promissory note (the “2022 Promissory Note”). The 2022 Promissory Note
is unsecured, interest-free and due on the earlier of June 29, 2023 (or such later date if the Company extends the time frame to complete
a business combination) or the date the Company consummates a business combination.
On March 22, 2023, June 26, 2023, September 12,
2023, September 26, 2023 and October 26, 2023, the Sponsor loaned the Company $200,000, $240,000, $150,000, $47,227 and $145,000 (collectively
the “2023 Promissory Notes”), respectively, to be used, in part, for extension deposits. Each Promissory Note is unsecured,
interest-free and due on the date the Company consummates a business combination.
As of March 31, 2024 and December 31, 2023, $937,252
was outstanding under the 2022 and 2023 Promissory Notes.
Related Party Loans
In addition, in order to finance transaction costs
in connection with searching for a target business or consummating an intended initial business combination, the initial stockholders,
officers, directors or their affiliates may, but are not obligated to, loan the Company funds as may be required. In the event that the
initial business combination does not close, the Company may use a portion of the working capital held outside the trust account to repay
such loaned amounts, but no proceeds from the Trust Account would be used for such repayment. Up to $1,500,000 of such loans may be convertible
into units at a price of $10.00 per unit at the option of the lender. The terms of such related party loans, if any, have not been determined
and no written agreements exist with respect to such loans.
As of March 31, 2024 and December 31, 2023, the
Company had no borrowings under the working capital loans.
Administrative Services Agreement
The Company entered into an Administrative Service
Agreement, commencing on the effective date of the IPO through the earlier of the Company’s consummation of a Business Combination
and its liquidation, to pay the Sponsor a total of $10,000 per month for office space, administrative and support services. The monthly
fees will be ceased upon completion of an initial Business Combination or liquidation. For the three months ended March 31, 2024 and 2023,
the Company incurred $30,000 each period in fees for these services. As of March 31, 2024 and December 31, 2023, total accrued expenses-related
party were $178,387 and $148,387, respectively.
Note 6 — Commitments and Contingencies
Registration Rights
The holders of the Founder Shares, Private Units (and
all underlying securities), and any shares that may be issued upon conversion of working capital loans will be entitled to registration
rights pursuant to a registration rights agreement signed on the effective date of IPO. The holders of the majority of these securities
are entitled to make up to three demands that the Company register such securities. The holders of the majority of the Founder Shares
can elect to exercise these registration rights at any time commencing three months prior to the date on which the Founder Shares
are to be released from escrow. The holders of a majority of the Private Units and units issued in payment of working capital loans
made to the Company can elect to exercise these registration rights at any time commencing on the date that the Company consummates a
Business Combination. In addition, the holders have certain “piggy-back” registration rights with respect to registration
statements filed subsequent to the consummation of a Business Combination. The Company will bear the expenses incurred in connection with
the filing of any such registration statements.
Underwriting Agreement
The Company has granted Ladenburg Thalmann, the
representative of the underwriters, a 45-day option from the date of this prospectus to purchase up to 750,000 additional Units to
cover over-allotments, if any, at the IPO price less the underwriting discounts and commissions. On October 4, 2022, the underwriters
partially exercised the over-allotment option to purchase 273,000 units which was closed on October 7, 2022, generating gross proceeds
to the Company of $2,730,000.
The underwriters were paid a cash underwriting
discount of 1.75% of the gross proceeds of the IPO, or $922,775. In addition, the underwriters are entitled to a deferred fee of 4.00%
of the gross proceeds of the IPO, or $2,109,200, which will be paid upon the closing of a Business Combination from the amounts held in
the Trust Account, subject to the terms of the underwriting agreement.
Note 7 — Stockholders’ Deficit
Common Stock — The Company
is authorized to issue 16,000,000 shares of common stock with a par value of $0.0001 per share. Holders of the common stock are entitled
to one vote for each share. As of December 31, 2021, there were 1,437,500 shares of common stock issued and outstanding, of which an aggregate
of up to 187,500 Founder Shares are subject to forfeiture to the extent that the underwriters’ over-allotment is not exercised in
full, so that the Initial Stockholders will collectively own 20% of the Company’s issued and outstanding shares after the IPO (assuming
the Initial Stockholders do not purchase any Public Shares in the IPO and excluding the Private Units). As a result of the underwriter’s
partial exercise of the over-allotment option on October 4, 2022, 119,250 shares of the Founder Shares were forfeited for no consideration
on October 7, 2022. As of March 31, 2024 and December 31, 2023, there were 1,662,623 shares of common stock issued and outstanding (excluding
837,857 shares subject to possible redemption).
Rights — Each holder of a
right will receive one-tenth (1/10) of one share of common stock upon consummation of a Business Combination, even if the holder of such
right redeemed all shares held by it in connection with a Business Combination. No fractional shares will be issued upon conversion of
the rights. No additional consideration will be required to be paid by a holder of rights in order to receive its additional shares upon
consummation of a Business Combination, as the consideration related thereto has been included in the unit purchase price paid for by
investors in the Initial Public Offering. If the Company enters into a definitive agreement for a Business Combination in which the Company
will not be the surviving entity, the definitive agreement will provide for the holders of rights to receive the same per share consideration
the holders of the common stock will receive in the transaction on an as-converted into common stock basis and each holder of a right
will be required to affirmatively convert its rights in order to receive one-tenth (1/10) of one share underlying each right (without
paying additional consideration). The shares issuable upon conversion of the rights will be freely tradable (except to the extent held
by affiliates of the Company).
If the Company is unable to complete a Business
Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of rights will not receive
any of such funds with respect to their rights, nor will they receive any distribution from the Company’s assets held outside of
the Trust Account with respect to such rights, and the rights will expire worthless. Further, there are no contractual penalties for failure
to deliver securities to the holders of the rights upon consummation of a Business Combination. Additionally, in no event will the Company
be required to net cash settle the rights. Accordingly, holders of the rights might not receive the shares of common stock underlying
the rights. As of March 31, 2024 and December 31, 2023, there were 5,542,373 rights issued and outstanding.
Warrants — Each redeemable
warrant entitles the holder thereof to purchase one share of common stock at a price of $11.50 per share, subject to adjustment as described
in this prospectus. The warrants will become exercisable on the later 30 days following the completion of an initial Business Combination
and 12 months from the date of this prospectus. The Company has agreed that as soon as practicable, but in no event later than 15 business days
after the closing of a Business Combination, the Company will use its best efforts to file, and within 60 business days following
a Business Combination to have declared effective, a registration statement covering the common stock issuable upon exercise of the warrants.
Notwithstanding the foregoing, if a registration statement covering the issuance of the common stock issuable upon exercise of the Public
Warrants is not effective within a specified period following the closing of the Company’s initial Business Combination, warrant
holders may, until such time as there is an effective registration statement and during any period when the Company shall have failed
to maintain an effective registration statement, exercise warrants on a cashless basis pursuant to an available exemption from registration
under the Securities Act. If an exemption from registration is not available, holders will not be able to exercise their warrants on a
cashless basis. The warrants will expire five years from the closing of the Company’s initial Business Combination at 5:00 p.m.,
New York City time or earlier upon redemption.
The Company may redeem the outstanding warrants:
| ● | in
whole and not in part; |
| ● | at
a price of $0.01 per warrant; |
| ● | upon
a minimum of 30 days’ prior written notice of redemption, which the Company refers to as the 30-day redemption period; |
| ● | if,
and only if, the last reported sale price of the Company’s common stock equals or exceeds $18.00 per share (as adjusted for stock
splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within a 30-trading day
period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the to the
warrant holders. |
If the Company calls the Public Warrants for redemption,
management will have the option to require all holders that wish to exercise the Public Warrants to do so on a “cashless basis,”
as described in the warrant agreement. In such event, each holder would pay the exercise price by surrendering the warrants for that number
of shares of common stock equal to the quotient obtained by dividing (x) the product of the number of shares of common stock underlying
the warrants, multiplied by the difference between the exercise price of the warrants and the “fair market value” (defined
below) by (y) the fair market value. The “fair market value” shall mean the average reported last sale price of the common
stock for the 10 trading days ending on the third trading day prior to the date on which the notice of redemption
is sent to the holders of warrants.
Except as described above, no warrants will be
exercisable and the Company will not be obligated to issue common stock unless at the time a holder seeks to exercise such warrant, a
prospectus relating to the common stock issuable upon exercise of the warrants is current and the common stock have been registered or
qualified or deemed to be exempt under the securities laws of the state of residence of the holder of the warrants. Under the terms of
the warrant agreement, the Company has agreed to use its best efforts to meet these conditions and to maintain a current prospectus relating
to the common stock issuable upon exercise of the warrants until the expiration of the warrants. However, the Company cannot assure that
it will be able to do so and, if the Company does not maintain a current prospectus relating to the common stock issuable upon exercise
of the warrants, holders will be unable to exercise their warrants and the Company will not be required to settle any such warrant exercise.
If the prospectus relating to the common stock issuable upon the exercise of the warrants is not current or if the common stock is not
qualified or exempt from qualification in the jurisdictions in which the holders of the warrants reside, the Company will not be required
to net cash settle or cash settle the warrant exercise, the warrants may have no value, the market for the warrants may be limited and
the warrants may expire worthless.
The Private Warrants have terms and provisions
that are identical to those of the warrants being sold as part of the units in the IPO except that the Private Warrants will be entitled
to registration rights. The Private Warrants (including the common stock issuable upon exercise of the Private Warrants) will not be transferable,
assignable or salable until 30 days after the completion of our initial business combination except to permitted transferees. As
of March 31, 2024 and December 31, 2023, there were 5,542,373 warrants issued and outstanding.
Note 8 — Fair Value Measurements
The fair value of the Company’s financial
assets and liabilities reflects management’s estimate of amounts that the Company would have received in connection with the sale
of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the
measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of
observable inputs (market data obtained from independent sources) and to minimize the use of unobservable inputs (internal assumptions
about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities
based on the observable inputs and unobservable inputs used in order to value the assets and liabilities:
Level 1: |
Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis. |
|
|
Level 2: |
Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active. |
|
|
Level 3: |
Unobservable inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability. |
The following tables present information about
the Company’s assets that are measured at fair value on a recurring basis at March 31, 2024 and December 31, 2023 and indicate the
fair value hierarchy of the valuation inputs the Company utilized to determine such fair value.
| |
March 31, 2024 | | |
Quoted Prices in Active Markets (Level 1) | | |
Significant Other Observable Inputs (Level 2) | | |
Significant Other Unobservable Inputs (Level 3) | |
Assets | |
| | |
| | |
| | |
| |
Marketable securities held in trust account | |
| 9,440,722 | | |
| 9,440,722 | | |
| — | | |
| — | |
| |
December 31, 2023 | | |
Quoted Prices in Active Markets (Level 1) | | |
Significant Other Observable Inputs (Level 2) | | |
Significant Other Unobservable Inputs (Level 3) | |
Assets | |
| | |
| | |
| | |
| |
Marketable securities held in trust account | |
| 9,299,336 | | |
| 9,299,336 | | |
| — | | |
| — | |
Note 9 — Subsequent Events
The Company evaluated subsequent events and transactions
that occurred after the balance sheet date up to the date that the financial statements were issued. Based on the review, management identified
the following subsequent event that require disclosure in the financial statements.
The Sponsor made a monthly deposit of $20,000
into the Trust Account from April 2024 to July 2024 and extended the period of time the Company has to consummate an initial Business
Combination from May 4, 2024 to August 4, 2024.
On April 23, 2024, Del Mar Global Advisors Limited
agreed to loan the Company $900,000, to be used to fund the extension of the Company, transaction costs related to the Business Combination,
and other operational expenses of the Company (the “Del Mar Promissory Note”). The Del Mar Promissory Note is unsecured, interest-free
and due upon the consummation of the Company’s business combination.
On April 30, 2024, June 4, 2024 and July 3, 2024,
the Sponsor loaned the Company $20,000 each time, to be used to fund the extension of the Company. The promissory notes are unsecured,
interest-free and due upon the consummation of the Company’s business combination.
Item 2. Management’s Discussion and Analysis of Financial
Condition and Results of Operations
References in this report (this “Quarterly
Report”) to “we,” “us” or the “Company” refer to Qomolangma Acquisition Corp. References to
our “management” or our “management team” refer to our officers and directors. The following discussion and analysis
of the Company’s financial condition and results of operations should be read in conjunction with the unaudited condensed financial
statements and the notes thereto contained elsewhere in this Quarterly Report. Certain information contained in the discussion and analysis
set forth below includes forward-looking statements that involve risks and uncertainties.
Special Note Regarding Forward-Looking Statements
This Quarterly Report includes “forward-looking
statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and
Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), that are not historical facts and involve
risks and uncertainties that could cause actual results to differ materially from those expected and projected. All statements, other
than statements of historical fact included in this Quarterly Report, including, without limitation, statements in this “Management’s
Discussion and Analysis of Financial Condition and Results of Operations” regarding the search for an initial business combination,
the Company’s financial position, business strategy and the plans and objectives of management for future operations, are forward-looking
statements. Words such as “expect,” “believe,” “anticipate,” “intend,” “estimate,”
“seek” and variations and similar words and expressions are intended to identify such forward-looking statements. Such forward-looking
statements relate to future events or future performance, but reflect management’s current beliefs, based on information currently
available. A number of factors could cause actual events, performance or results to differ materially from the events, performance and
results discussed in the forward-looking statements. For information identifying important factors that could cause actual results to
differ materially from those anticipated in the forward-looking statements, please refer to the Risk Factors section of the Company’s
final prospectus for its initial public offering filed with the U.S. Securities and Exchange Commission (the “SEC”). The Company’s
filings with the SEC can be accessed on the EDGAR section of the SEC’s website at www.sec.gov. Except as expressly required by applicable
securities law, the Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result
of new information, future events or otherwise.
Overview
We are a blank check company incorporated in Delaware
on May 6, 2021. We were formed for the purpose of entering into a merger, share exchange, asset acquisition, stock purchase, recapitalization,
reorganization or other similar business combination with one or more target businesses, which we refer to herein as our “initial
business combination.” Our efforts to identify a prospective target business are not limited to any particular industry or geographic
region, although we intend to pursue target businesses that are strategically significant in the Asian markets and focus on businesses
with a total enterprise value of between $300,000,000 and $500,000,000. We intend to utilize cash derived from the proceeds of our initial
public offering (“IPO” as defined below) and the private placement of Private Units, our securities, debt or a combination
of cash, securities and debt, in effecting our initial business combination.
We expect to continue to incur significant costs
in the pursuit of our acquisition plans. We cannot assure you that our plans to complete an initial business combination will be successful.
Recent Developments
On June 29, 2023, the Company held a special meeting
of stockholders (the “June Special Meeting”). At the June Special Meeting, the stockholders amended the Company’s Amended
and Restated Certificate of Incorporation to allow the Company to consummate a business combination until August 4, 2023 (or up to August
4, 2024 if the time to complete a business combination is extended as described herein) to consummate a Business Combination. In addition,
if the Company anticipates that it may not be able to consummate a Business Combination by August 4, 2023, the Company may extend the
period of time to consummate a Business Combination up to twelve times, each by an additional one month (for a total of 22 months to complete
a Business Combination) (the “Combination Period”). In order to extend the time available for the Company to consummate a
Business Combination, the Company’s insiders or their affiliates or designees, upon five days’ advance notice prior to the
applicable deadline, must deposit into the Trust Account the lesser of $0.033 per outstanding share and $80,000 per month, on or prior
to the date of the applicable deadline, for each extension.
In connection with the June Special Meeting, an
aggregate of 2,126,934 shares with redemption value of approximately $22,141,383 (or $10.41 per share) of the Company’s common stock
were tendered for redemption.
On June 29, 2023, the Sponsor made a deposit of
$240,000 to the Trust Account and extended the period of time the Company has to consummate an initial Business Combination from July
4, 2023 to October 4, 2023.
On September 12, 2023, the Company held a special
meeting of stockholders (the “September Special Meeting”). At the September Special Meeting, the stockholders amended the
Company’s Amended and Restated Certificate of Incorporation to allow the Company to undertake an initial business combination with
an entity or business, with a physical presence, operation, or other significant ties to China (a “China-based Target”)
or which may subject the post-business combination business to the laws, regulations and policies of China (including Hong Kong and
Macao), or entity or business that conducts operations in China through variable interest entities, or VIEs, pursuant to a series of contractual
arrangements with the VIE and its shareholders on one side, and a China-based subsidiary of the China-based Target, on the other
side.
In connection with the September Special Meeting,
an aggregate of 1,233,054 shares with redemption value of approximately $13,082,703 (or $10.61 per share) of the Company’s common
stock were tendered for redemption.
On September 26, 2023 and October 31, 2023, the
Sponsor made a deposit of $47,277 (which reflects a reduction of $18,377 previously deposited for the September monthly extension fee
as a result of the Company’s public shares redeemed on September 12 and applied to the October monthly extension fee of $65,604)
and $63,129, respectively, to the Trust Account and extended the period of time the Company has to consummate an initial Business Combination
from October 4, 2023 to December 3, 2023.
On October 26, 2023, the Sponsor loaned the Company
$145,000 to be used, in part, for extension deposits and transaction costs related to the Business Combination. The Promissory Note is
unsecured, interest-free and due on the date the Company consummates a business combination.
On December 7, 2023, the Company held a special
meeting of stockholders. At the special meeting, holders of 3,575,635 shares of common stock of the Company were present in person or
by proxy, representing 81.18% of the total shares of common stock as of November 15, 2023, the record date for the special meeting, and
constituting a quorum for the transaction of business. At the special meeting, the stockholders approved further amendments to our amended
and restated certificate of incorporation and Trust Agreement to reduce the amount the Company must deposit into the Trust Account to
extend the date on which the trustee must liquidate the trust account established by the Company in connection with the IPO to the lesser
of $0.033 per outstanding share and $20,000 for each one-month extension.
On November 29, 2023, the Sponsor made a deposit
of $63,129 (which did not reflect a reduction of $38,043 extension fee as a result of the Company’s December 2023 public shares
redemption) into the Trust Account and extended the period of time the Company has to consummate an initial Business Combination from
December 4, 2023 to January 4, 2024.
The Sponsor made a monthly deposit of $20,000
into the Trust Account from December 2023 to July 2024 and extended the period of time the Company has to consummate an initial Business
Combination from January 4, 2024 to August 4, 2024.
Results of Operations
We have neither engaged in any operations nor
generated any operating revenues to date. Our only activities through March 31, 2024 were organizational activities and those necessary
to prepare for our IPO, which is described below, and subsequent to the IPO, identifying a target company for an initial business combination.
We do not expect to generate any operating revenues until after the completion of our initial business combination.
We expect to generate non-operating income in
the form of interest income on investments held in the Trust Account. We expect that we will incur increased expenses as a result of being
a public company (for legal, financial reporting, accounting and auditing compliance), as well as for due diligence expenses in connection
with searching for, and completing, a Business Combination.
For the three months ended March 31, 2024,
we had a net loss of $3,055, which consisted of loss of $100,231 derived from general and administrative expenses of $94,131 and
franchise tax expense of $6,100, and income tax expense of $24,210, offset by interest earned on investments held in the Trust
Account of $121,386.
For the three months ended March 31, 2023, we
had a net loss of $224,171, which consisted of loss of $679,020 derived from general and administrative expenses of $666,320 and franchise
tax expense of $12,700, and income tax expense of $117,533, offset by interest earned on investments held in the Trust Account of $572,382.
For the three months ended March 31, 2024, cash balance was decreased
by $2,913, which consisted of cash used in operating activities of $2,913.
For the three months ended March 31, 2023, cash
balance was decreased by $28,733, which consisted of cash used in operating activities of $274,162, offset by cash provided by investing
activities of $45,429 and cash provided by financing activities of $200,000.
Liquidity, Capital Resources and Going Concern
On October 4, 2022, we completed our initial public
offering (“IPO”) of 5,000,000 units (the “Public Units”), at $10.00 per Public Unit, generating gross proceeds
of $50,000,000. Each Public Unit consisted of one share of common stock, par value $0.0001, one redeemable warrant and one right to receive
one-tenth (1/10) of a share of common stock upon the consummation of an initial business combination. Simultaneously with the closing
of the IPO, we completed the sale of 260,500 units (the “Private Units”) in a private placement, at a price of $10.00 per
Private Unit, generating gross proceeds of $2,605,000.
We granted the underwriters in the IPO a 45-day
option to purchase up to 750,000 additional Public Units to cover over-allotments, if any. On October 4, 2022, the underwriters partially
exercised the over-allotment option to purchase 273,000 Units (“Over-Allotment Option Units”) at $10.00 per Unit, which was
closed on October 7, 2022 generating total gross proceeds of $2,730,000. On October 7, 2022, simultaneously with the sale of the Over-Allotment
Option Units, the Company consummated the private placement of an additional 8,873 Private Units generating gross proceeds of $88,725.
Simultaneously with the closing of the IPO, we issued Ladenburg Thalmann & Co., Inc., the underwriter, 75,000 shares of common stock.
Following the IPO and the private placement (including
the Over-Allotment Option Units and the Over-Allotment Private Units), a total of $53,520,950 was placed in a trust account located in
the United States established for the benefit of the Company’s public stockholders (the “Trust Account”) maintained
by American Stock Transfer & Trust Company as a trustee and will be invested only in U.S. government treasury bills with a maturity
of 185 days or less or in money market funds meeting certain conditions under Rule 2a-7 under the Investment Company Act of 1940, as amended,
and that invest only in direct U.S. government treasury obligations.
We intend to use substantially all of the net
proceeds of the IPO and the private placement, including the funds held in the Trust Account, in connection with our initial business
combination and to pay our expenses relating thereto, including deferred underwriting discounts and commissions payable to the underwriters
in the IPO in an amount equal to 4.0% of the total gross proceeds raised in the IPO upon consummation of our initial business combination.
To the extent that our capital stock is used in whole or in part as consideration to effect our initial business combination, the remaining
proceeds held in the Trust Account as well as any other net proceeds not expended will be used as working capital to finance the operations
of the target business. Such working capital funds could be used in a variety of ways including continuing or expanding the target business’
operations, for strategic acquisitions and for marketing, research and development of existing or new products. Such funds could also
be used to repay any operating expenses or finders’ fees which we had incurred prior to the completion of our initial business combination
if the funds available to us outside of the Trust Account were insufficient to cover such expenses.
As of March 31, 2024, the Company had $6,309 of
cash held outside its Trust Account and a working capital deficit of $2,981,617. On March 22, 2023, June 26, 2023, September 12, 2023,
September 26, 2023 and October 26, 2023, the Sponsor loaned the Company $200,000, $240,000, $150,000, $47,227, and $145,000, respectively,
to be used, in part, for extension deposits. As a result of the Sponsor’s deposit of $63,129 each time to the Trust Account on October
31, 2023 and November 29, 2023, and the monthly deposits of $20,000 into the Trust Account from December 2023 to July 2024, the Company
has until August 4, 2024 (unless the Company further extends the time to complete a Business Combination) to consummate a Business Combination.
It is uncertain that the Company will be able to consummate a Business Combination by this time. If a Business Combination is not consummated
by this date, there will be a mandatory liquidation and subsequent dissolution.
The Company expects to continue to incur significant
professional costs to remain as a publicly traded company and to incur significant transaction costs in pursuit of the consummation of
a Business Combination. The Company may need to obtain additional financing either to complete its Business Combination or because it
becomes obligated to redeem a significant number of public shares upon consummation of its Business Combination, in which case the Company
may issue additional securities or incur debt in connection with such Business Combination. Subject to compliance with applicable securities
laws, the Company would only complete such financing simultaneously with the completion of our Business Combination. If the Company is
unable to complete its Business Combination because it does not have sufficient funds available, it will be forced to cease operations
and liquidate the Trust Account. In addition, following the Business Combination, if cash on hand is insufficient, the Company may need
to obtain additional financing in order to meet its obligations.
In connection with the Company’s assessment
of going concern considerations in accordance with Financial Accounting Standard Board’s Accounting Standards Update (“ASU”)
2014-15, “Disclosures of Uncertainties about an Entity’s Ability to Continue as a Going Concern”, management has determined
that these conditions raise substantial doubt about the Company’s ability to continue as a going concern. In addition, if the Company
is unable to complete a Business Combination within the Combination Period, the Company’s board of directors would proceed to commence
voluntary liquidation and thereby a formal dissolution of the Company. There is no assurance that the Company’s plans to consummate
a Business Combination will be successful within the Combination Period. As a result, management has determined that such additional condition
also raises substantial doubt about the Company’s ability to continue as a going concern. The financial statement does not include
any adjustments that might result from the outcome of this uncertainty.
Off-Balance Sheet Arrangements
We have no obligations, assets or liabilities,
which would be considered off-balance sheet arrangements as of March 31, 2024 and December 31, 2023. We do not participate in transactions
that create relationships with unconsolidated entities or financial partnerships, often referred to as variable interest entities, which
would have been established for the purpose of facilitating off-balance sheet arrangements. We have not entered into any off-balance sheet
financing arrangements, established any special purpose entities, guaranteed any debt or commitments of other entities, or purchased any
non-financial assets.
Contractual Obligations
Promissory Notes – Related Party
The Company received $155,025 from the Sponsor
at the closing of IPO to finance transaction costs in connection with searching for a target business. On October 7, 2022, the Sponsor
converted the outstanding balance of $155,025 to a promissory note (the “2022 Promissory Note”). On March 22, 2023, June 26,
2023, September 12, 2023, September 26, 2023, and October 26, 2023, the Sponsor loaned the Company $200,000, $240,000, $150,000, $47,227
and $145,000 (collectively the “2023 Promissory Notes”), respectively, to be used, in part, for extension deposits. Each of
the 2023 Promissory Notes is unsecured, interest-free and due on the date the Company consummates a business combination. As of
March 31, 2024 and December 31, 2023, $937,252 was outstanding under the 2022 and 2023 Promissory Notes.
Administrative Services Agreement
We have entered into an administrative services
agreement pursuant to which we will pay the Sponsor a total of $10,000 per month (subject to deferral as described herein) for office
space, utilities, secretarial and administrative support services. Upon completion of our initial business combination or our liquidation,
we will cease paying these monthly fees.
Registration Rights
The holders of the founder shares, private placement
units, and units that may be issued on conversion of working capital loans (and any securities underlying the private placement units
and the working capital loans) are entitled to registration rights pursuant to a registration rights agreement signed on the effective
date of the IPO requiring us to register such securities for resale. The holders of these securities are entitled to make up to three
demands, excluding short form demands, that we register such securities. In addition, the holders have certain “piggy-back”
registration rights with respect to registration statements filed subsequent to our completion of our initial business combination and
rights to require us to register for resale such securities pursuant to Rule 415 under the Securities Act. We will bear the expenses incurred
in connection with the filing of any such registration statements.
Underwriting Agreement
Pursuant to an underwriting agreement in connection
with the IPO, we granted Ladenburg Thalmann, the representative of the underwriters, a 45-day option to purchase up to 750,000 additional
Units to cover over-allotments, if any, at the IPO price less the underwriting discounts and commissions. On October 4, 2022, the underwriters
partially exercised the over-allotment option to purchase 273,000 units at an offering price of $10.00 per Unit for an aggregate purchase
price of $2,730,000.
The underwriters were paid a cash underwriting
discount of 1.75% of the gross proceeds of the IPO, or $922,775. In addition, the underwriters are entitled to a deferred fee of 4.00%
of the gross proceeds of the IPO, or $2,109,200, which will be paid upon the closing of a Business Combination from the amounts held in
the Trust Account, subject to the terms of the underwriting agreement.
Critical Accounting Estimates
The preparation of financial statements and related
disclosures in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets
and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and income and expenses during
the period reported. Actual results could materially differ from those estimates. We have not identified critical accounting estimates.
Recent accounting pronouncements
In December 2023, the FASB issued Accounting Standards
Update 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosure” (“ASU 2023-09”). ASU 2023-09
mostly requires, on an annual basis, disclosure of specific categories in an entity’s effective tax rate reconciliation and income
taxes paid disaggregated by jurisdiction. The incremental disclosures may be presented on a prospective or retrospective basis. The ASU
is effective for fiscal years beginning after December 15, 2024 with early adoption permitted. The Company is currently assessing the
impact, if any, that ASU 2023-09 would have on its financial position, results of operations or cash flows.
Management does not believe that any other recently
issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s financial
statement.
Item 3. Quantitative and Qualitative Disclosures About Market Risk
As a smaller reporting company, we are not required
to make disclosures under this Item.
Item 4. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
Disclosure controls and procedures are designed
to ensure that information required to be disclosed by us in our Exchange Act reports is recorded, processed, summarized, and reported
within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our
management, including our principal executive officer and principal financial officer or persons performing similar functions, as appropriate
to allow timely decisions regarding required disclosure.
Under the supervision and with the participation
of our management, including our principal executive officer and principal financial and accounting officer, we conducted an evaluation
of the effectiveness of our disclosure controls and procedures as of the fiscal quarter ended March 31, 2024, as such term is defined
in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Based on this evaluation, our principal executive officer and principal financial
and accounting officer have concluded that during the period covered by this report, our disclosure controls and procedures were effective.
Changes in Internal Control Over Financial
Reporting
During the quarter ended March 31, 2024, there
has been no change in our internal control over financial reporting that has materially affected, or is reasonably likely to materially
affect, our internal control over financial reporting.
Part
II – Other Information
Item 1. Legal Proceedings
None.
Item 1A. Risk Factors
As a smaller reporting company, we are not required
to make disclosures under this Item. We have provided a comprehensive list of risk factors in the final prospectus for our IPO as filed
with the SEC on October 3, 2022, and the Proxy Statements as filed with the SEC on June 13, 2023 and August 21, 2023.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
On October 4, 2022, we consummated the IPO of
5,000,000 Public Units, each Public Unit consisting of one share of common stock, one redeemable warrant and one right, for $10.00 per
Public Unit, generating gross proceeds of $50,000,000. Each warrant entitles the holder thereof to purchase one share of common stock
at a price of $11.50 per share, subject to adjustment. Each right entitles the holder thereof to receive one-tenth (1/10) of a share of
common stock upon the consummation of an initial business combination. We had granted the underwriters in the IPO a 45-day option to purchase
up to 750,000 additional Public Units to cover over-allotments.
Subsequently, the underwriter partially exercised
the over-allotment option in full and, on October 7, 2022, purchased 273,000 Public Units at an offering price of $10.00 per Public Unit
for an aggregate purchase price of $2,730,000. The securities in the IPO, including the exercise by the underwriters of the over-allotment
option, were registered under the Securities Act on a registration statement on Form S-1 (No. 333-265447). The SEC declared the registration
statement effective on September 29, 2022.
On October 4, 2022, simultaneously with the closing
of the IPO, we sold an aggregate of 260,500 Private Units in a private placement with the Sponsor, at a price of $10.00 per Private Unit,
generating gross proceeds of $2,605,000. The Private Units are identical to the units sold in the IPO, except that (a) the Private Units
and underlying securities will not be transferable, assignable or salable until the consummation of our initial business combination,
except to permitted transferees, and (b) the private warrants, so long as they are held by the initial purchasers or their permitted transferees,
(i) will not be redeemable by us, (ii) may be exercised by the holders on a cashless basis, and (iii) will be entitled to registration
rights.
On October 7, 2022, simultaneously with the closing
of the exercise of the over-allotment option, we consummated the sale of an additional aggregate of 8,873 Private Units in a private placement
to the Sponsor, at a purchase price of $10.00 per Private Unit, generating gross proceeds of $88,725. The Private Units were issued pursuant
to the exemption from registration contained in Section 4(a)(2) of the Securities Act.
A total of $53,520,950 of the net proceeds from
the sale of the Public Units in the IPO and the private placement of the Private Units on October 4, 2022 and October 7, 2022 were deposited
in a trust account established for the benefit of the Company’s public stockholders at Bank of America, N.A. maintained by American
Stock Transfer & Trust Company, acting as trustee.
For a description of the use of the proceeds generated
in our IPO, see Part I, Item 2 – Management’s Discussion and Analysis of Financial Condition and Results of Operations of
this Quarterly Report.
Item 3. Defaults Upon Senior Securities
None.
Item 4. Mine Safety Disclosures
Not applicable.
Item 5. Other Information
None.
Item 6. Exhibits
The following exhibits are filed as part of, or
incorporated by reference into, this Quarterly Report.
Exhibit No. |
|
Description |
3.1 |
|
Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Registration Statement on Form S-1/A filed with the Securities & Exchange Commission on September 26, 2022). |
3.2 |
|
Form of Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.2 to the Registration Statement on Form S-1/A filed with the Securities & Exchange Commission on September 26, 2022). |
3.3 |
|
Bylaws (incorporated by reference to Exhibit 3.3 to the Registration Statement on Form S-1/A filed with the Securities & Exchange Commission on September 26, 2022). |
4.1 |
|
Specimen Unit Certificate (incorporated by reference to Exhibit 4.1 to the Registration Statement on Form S-1/A filed with the Securities & Exchange Commission on September 26, 2022). |
4.2 |
|
Specimen Common Stock Certificate (incorporated by reference to Exhibit 4.2 to the Registration Statement on Form S-1/A filed with the Securities & Exchange Commission on September 26, 2022). |
4.3 |
|
Specimen Warrant Certificate(incorporated by reference to Exhibit 4.3 to the Registration Statement on Form S-1/A filed with the Securities & Exchange Commission on September 26, 2022). |
4.4 |
|
Specimen Right Certificate (incorporated by reference to Exhibit 4.4 to the Registration Statement on Form S-1/A filed with the Securities & Exchange Commission on September 26, 2022). |
4.5 |
|
Form of Warrant Agreement between American Stock Transfer & Trust Company, LLC and the Registrant (incorporated by reference to Exhibit 4.5 to the Registration Statement on Form S-1/A filed with the Securities & Exchange Commission on September 26, 2022). |
4.6 |
|
Form of Rights Agreement between American Stock Transfer & Trust Company, LLC and the Registrant (incorporated by reference to Exhibit 4.6 to the Registration Statement on Form S-1/A filed with the Securities & Exchange Commission on September 26, 2022). |
10.1 |
|
Promissory Note, dated as of September 5, 2021 issued to Qomolangma Investments LLC (incorporated by reference to Exhibit 10.1 to the Registration Statement on Form S-1/A filed with the Securities & Exchange Commission on September 26, 2022). |
10.2* |
|
Promissory Note, dated as of October 7, 2022 issued to Qomolangma Investments LLC. |
10.3* |
|
Promissory Note, dated as of March 22, 2023 issued to Qomolangma Investments LLC. |
10.4* |
|
Promissory Note, dated as of June 26, 2023 issued to Qomolangma Investments LLC. |
10.5* |
|
Promissory Note, dated as of September 12, 2023 issued to Qomolangma Investments LLC. |
10.6* |
|
Promissory Note, dated as of September 26, 2023 issued to Qomolangma Investments LLC. |
10.7* |
|
Promissory Note, dated as of October 26, 2023 issued to Qomolangma Investments LLC. |
10.8* |
|
Promissory Note, dated as of April 23, 2024 issued to Del Mar Global Advisors Limited. |
10.9* |
|
Promissory Note, dated as of April 30, 2024 issued to Qomolangma Investments LLC. |
10.10* |
|
Promissory Note, dated as of June 4, 2024 issued to Qomolangma Investments LLC. |
10.11 |
|
Form of Letter Agreement among the Registrant, and its officers, directors and Qomolangma Investments LLC (incorporated by reference to Exhibit 10.2 to the Registration Statement on Form S-1/A filed with the Securities & Exchange Commission on September 26, 2022). |
10.12 |
|
Form of Investment Management Trust Agreement between American Stock Transfer & Trust Company, LLC and the Registrant (incorporated by reference to Exhibit 10.3 to the Registration Statement on Form S-1/A filed with the Securities & Exchange Commission on September 26, 2022). |
10.13 |
|
Form of Registration Rights Agreement between the Registrant and certain security holders (incorporated by reference to Exhibit 10.4 to the Registration Statement on Form S-1/A filed with the Securities & Exchange Commission on September 26, 2022). |
10.14 |
|
Subscription Agreement, dated September 25, 2021 between the Registrant and Qomolangma Investments LLC (incorporated by reference to Exhibit 10.5 to the Registration Statement on Form S-1/A filed with the Securities & Exchange Commission on September 26, 2022). |
10.15 |
|
Subscription Agreement, dated September 25, 2021 between the Registrant and Jonathan Myers (incorporated by reference to Exhibit 10.6 to the Registration Statement on Form S-1/A filed with the Securities & Exchange Commission on September 26, 2022). |
10.16 |
|
Subscription Agreement, dated September 25, 2021 between the Registrant and Hao Shen (incorporated by reference to Exhibit 10.7 to the Registration Statement on Form S-1/A filed with the Securities & Exchange Commission on September 26, 2022). |
10.17 |
|
Subscription Agreement, dated September 25, 2021 between the Registrant and Jialuan Ma (incorporated by reference to Exhibit 10.8 to the Registration Statement on Form S-1/A filed with the Securities & Exchange Commission on September 26, 2022). |
10.18 |
|
Subscription Agreement, dated September 25, 2021 between the Registrant and Yong Seog Jung (incorporated by reference to Exhibit 10.9 to the Registration Statement on Form S-1/A filed with the Securities & Exchange Commission on September 26, 2022). |
10.19 |
|
Subscription Agreement, dated September 25, 2021 between the Registrant and Lin Shi (incorporated by reference to Exhibit 10.10 to the Registration Statement on Form S-1/A filed with the Securities & Exchange Commission on September 26, 2022). |
10.20 |
|
Private Placement Units Purchase Agreement between the Registrant and Qomolangma Investments LLC (incorporated by reference to Exhibit 10.11 to the Registration Statement on Form S-1/A filed with the Securities & Exchange Commission on September 26, 2022). |
10.21 |
|
Form of Indemnity Agreement (incorporated by reference to Exhibit 10.12 to the Registration Statement on Form S-1/A filed with the Securities & Exchange Commission on September 26, 2022). |
10.22 |
|
Form of Administrative Services Agreement, by and between the Registrant and Qomolangma Investments LLC (incorporated by reference to Exhibit 10.13 to the Registration Statement on Form S-1/A filed with the Securities & Exchange Commission on September 26, 2022). |
31.1* |
|
Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |
31.2* |
|
Certification of Principal Financial Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |
32.1** |
|
Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |
32.2** |
|
Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |
101.INS* |
|
Inline XBRL Instance Document |
101.SCH* |
|
Inline XBRL Taxonomy Extension Schema Document |
101.CAL* |
|
Inline XBRL Taxonomy Extension Calculation Linkbase Document |
101.DEF* |
|
Inline XBRL Taxonomy Extension Definition Linkbase Document |
101.LAB* |
|
Inline XBRL Taxonomy Extension Labels Linkbase Document |
101.PRE* |
|
Inline XBRL Taxonomy Extension Presentation Linkbase Document |
104* |
|
Cover Page Interactive Data File (Embedded within the Inline XBRL document and included in Exhibit) |
** |
Furnished herewith. This certification is being furnished solely to accompany this report pursuant to 18 U.S.C. Section 1350, and is not being filed for purposes of Section 18 of the Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filings of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. |
Signatures
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
QOMOLANGMA ACQUISITION CORP. |
|
|
|
Date: July 25, 2024 |
By: |
/s/ Jonathan P. Myers |
|
Name: |
Jonathan P. Myers |
|
Title: |
Chief Executive Officer
(Principal Executive Officer) |
Date: July 25, 2024 |
By: |
/s/ Hao Shen |
|
Name: |
Hao Shen |
|
Title: |
Chief Financial Officer
(Principal Financial and Accounting Officer) |
30
5273000
5273000
5273000
837857
0.09
0.14
1662623
1662623
0.05
0.58
1662623
1662623
5273000
837857
0.05
0.09
0.14
0.58
P5Y
false
--12-31
Q1
0001894210
0001894210
2024-01-01
2024-03-31
0001894210
qomo:UnitsMember
2024-01-01
2024-03-31
0001894210
qomo:CommonStocksMember
2024-01-01
2024-03-31
0001894210
qomo:WarrantsMember
2024-01-01
2024-03-31
0001894210
qomo:RightMember
2024-01-01
2024-03-31
0001894210
2024-07-25
0001894210
2024-03-31
0001894210
2023-12-31
0001894210
us-gaap:RelatedPartyMember
2024-03-31
0001894210
us-gaap:RelatedPartyMember
2023-12-31
0001894210
2023-01-01
2023-03-31
0001894210
qomo:RedeemableCommonStockMember
2024-01-01
2024-03-31
0001894210
qomo:RedeemableCommonStockMember
2023-01-01
2023-03-31
0001894210
qomo:NonredeemableCommonStockMember
2024-01-01
2024-03-31
0001894210
qomo:NonredeemableCommonStockMember
2023-01-01
2023-03-31
0001894210
us-gaap:CommonStockMember
2023-12-31
0001894210
us-gaap:RetainedEarningsMember
2023-12-31
0001894210
us-gaap:CommonStockMember
2024-01-01
2024-03-31
0001894210
us-gaap:RetainedEarningsMember
2024-01-01
2024-03-31
0001894210
us-gaap:CommonStockMember
2024-03-31
0001894210
us-gaap:RetainedEarningsMember
2024-03-31
0001894210
us-gaap:CommonStockMember
2022-12-31
0001894210
us-gaap:AdditionalPaidInCapitalMember
2022-12-31
0001894210
us-gaap:RetainedEarningsMember
2022-12-31
0001894210
2022-12-31
0001894210
us-gaap:CommonStockMember
2023-01-01
2023-03-31
0001894210
us-gaap:AdditionalPaidInCapitalMember
2023-01-01
2023-03-31
0001894210
us-gaap:RetainedEarningsMember
2023-01-01
2023-03-31
0001894210
us-gaap:CommonStockMember
2023-03-31
0001894210
us-gaap:AdditionalPaidInCapitalMember
2023-03-31
0001894210
us-gaap:RetainedEarningsMember
2023-03-31
0001894210
2023-03-31
0001894210
srt:MinimumMember
2024-01-01
2024-03-31
0001894210
srt:MaximumMember
2024-01-01
2024-03-31
0001894210
us-gaap:IPOMember
2022-10-04
2022-10-04
0001894210
qomo:PublicUnitsMember
us-gaap:IPOMember
2022-10-04
0001894210
2022-10-04
2022-10-04
0001894210
qomo:PrivateUnitsMember
2024-01-01
2024-03-31
0001894210
qomo:PrivateUnitsMember
2024-03-31
0001894210
qomo:PrivateUnitsMember
2024-01-01
2024-03-31
0001894210
us-gaap:OverAllotmentOptionMember
2024-01-01
2024-03-31
0001894210
us-gaap:OverAllotmentOptionMember
2022-10-04
2022-10-04
0001894210
qomo:PublicUnitsMember
2022-10-04
0001894210
us-gaap:OverAllotmentOptionMember
2022-10-07
2022-10-07
0001894210
us-gaap:PrivatePlacementMember
2024-01-01
2024-03-31
0001894210
us-gaap:IPOMember
2022-10-07
2022-10-07
0001894210
us-gaap:OverAllotmentOptionMember
2022-10-04
0001894210
us-gaap:OverAllotmentOptionMember
2022-10-07
0001894210
qomo:BusinessCombinationMember
2024-03-31
0001894210
qomo:BusinessCombinationMember
2024-01-01
2024-03-31
0001894210
us-gaap:CommonStockMember
2024-03-31
0001894210
us-gaap:CommonStockMember
2024-01-01
2024-03-31
0001894210
srt:MinimumMember
us-gaap:CommonStockMember
2024-03-31
0001894210
qomo:BusinessCombinationMember
2023-06-29
0001894210
srt:MaximumMember
2024-03-31
0001894210
us-gaap:DepositsMember
2023-10-31
0001894210
us-gaap:DepositsMember
2023-11-29
0001894210
2023-12-07
2023-12-07
0001894210
2023-11-15
0001894210
2023-11-29
0001894210
2023-11-29
2023-11-29
0001894210
qomo:SponsorMember
2024-01-01
2024-03-31
0001894210
2023-03-22
0001894210
2023-06-26
0001894210
2023-09-12
0001894210
2023-09-26
0001894210
2023-10-26
0001894210
qomo:SponsorMember
2023-10-31
0001894210
qomo:SponsorMember
2023-11-29
0001894210
qomo:SponsorMember
2024-01-01
2024-03-31
0001894210
2022-08-16
2022-08-16
0001894210
qomo:PublicUnitsMember
2024-03-31
0001894210
qomo:RedeemableShareMember
2024-01-01
2024-03-31
0001894210
qomo:NonRedeemableSharesMember
2024-01-01
2024-03-31
0001894210
qomo:RedeemableShareMember
2023-01-01
2023-03-31
0001894210
qomo:NonRedeemableSharesMember
2023-01-01
2023-03-31
0001894210
2022-01-01
2022-12-31
0001894210
2023-01-01
2023-12-31
0001894210
us-gaap:IPOMember
2022-10-04
0001894210
qomo:PublicRightMember
2024-01-01
2024-03-31
0001894210
qomo:PublicWarrantMember
2024-01-01
2024-03-31
0001894210
qomo:PublicWarrantMember
2024-03-31
0001894210
qomo:SponsorMember
us-gaap:PrivatePlacementMember
2024-01-01
2024-03-31
0001894210
qomo:SponsorMember
us-gaap:PrivatePlacementMember
2024-03-31
0001894210
qomo:SponsorMember
2024-03-31
0001894210
us-gaap:PrivatePlacementMember
2024-03-31
0001894210
qomo:FounderSharesMember
us-gaap:CommonStockMember
2021-09-25
2021-09-25
0001894210
qomo:FounderSharesMember
2021-09-25
2021-09-25
0001894210
qomo:FounderSharesMember
2021-09-25
0001894210
us-gaap:OverAllotmentOptionMember
2024-03-31
0001894210
2022-10-07
2022-10-07
0001894210
qomo:FounderSharesMember
2024-03-31
0001894210
us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember
2024-01-01
2024-03-31
0001894210
us-gaap:IPOMember
2024-01-01
2024-03-31
0001894210
qomo:SponsorMember
2024-01-01
2024-03-31
0001894210
qomo:AdministrativeServicesAgreementMember
2024-01-01
2024-03-31
0001894210
qomo:AdministrativeServicesAgreementMember
2023-01-01
2023-03-31
0001894210
qomo:UnderwritingAgreementMember
2024-01-01
2024-03-31
0001894210
us-gaap:CommonStockMember
2021-12-31
0001894210
2021-01-01
2021-12-31
0001894210
us-gaap:RightsMember
2024-03-31
0001894210
us-gaap:RightsMember
2023-12-31
0001894210
us-gaap:WarrantMember
us-gaap:CommonStockMember
2024-03-31
0001894210
us-gaap:WarrantMember
2024-03-31
0001894210
qomo:PublicWarrantMember
2024-01-01
2024-03-31
0001894210
qomo:PublicWarrantMember
2024-03-31
0001894210
us-gaap:WarrantMember
2023-12-31
0001894210
us-gaap:FairValueInputsLevel1Member
us-gaap:FairValueMeasurementsRecurringMember
2024-03-31
0001894210
us-gaap:FairValueInputsLevel2Member
us-gaap:FairValueMeasurementsRecurringMember
2024-03-31
0001894210
us-gaap:FairValueInputsLevel3Member
us-gaap:FairValueMeasurementsRecurringMember
2024-03-31
0001894210
us-gaap:FairValueInputsLevel1Member
us-gaap:FairValueMeasurementsRecurringMember
2023-12-31
0001894210
us-gaap:FairValueInputsLevel2Member
us-gaap:FairValueMeasurementsRecurringMember
2023-12-31
0001894210
us-gaap:FairValueInputsLevel3Member
us-gaap:FairValueMeasurementsRecurringMember
2023-12-31
0001894210
srt:ScenarioForecastMember
qomo:SponsorMember
2024-04-01
2024-07-31
0001894210
qomo:DelMarGlobalAdvisorsLimitedMember
us-gaap:SubsequentEventMember
2024-04-23
0001894210
qomo:SponsorMember
us-gaap:SubsequentEventMember
2024-04-30
0001894210
srt:ScenarioForecastMember
qomo:SponsorMember
2024-06-03
xbrli:shares
iso4217:USD
iso4217:USD
xbrli:shares
xbrli:pure
qomo:Days
THIS NOTE HAS NOT BEEN REGISTERED
UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”). THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT ONLY AND MAY
NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF REGISTRATION OF THE RESALE THEREOF UNDER THE SECURITIES ACT OR AN OPINION OF COUNSEL
REASONABLY SATISFACTORY IN FORM, SCOPE AND SUBSTANCE TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED.
Notice shall be deemed
given on the earlier of (i) actual receipt by the receiving party, (ii) the date shown on a facsimile transmission confirmation, (iii)
the date reflected on a signed delivery receipt, or (iv) two (2) Business Days following tender of delivery or dispatch by express mail
or delivery service.
IN WITNESS WHEREOF, Maker, intending
to be legally bound hereby, has caused this Note to be duly executed on the day and year first above written.
THIS NOTE HAS NOT
BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”). THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT
ONLY AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF REGISTRATION OF THE RESALE THEREOF UNDER THE SECURITIES ACT OR AN
OPINION OF COUNSEL REASONABLY SATISFACTORY IN FORM, SCOPE AND SUBSTANCE TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED.
relating to its bankruptcy, insolvency,
reorganization, rehabilitation or other similar action, or the consent by it to the appointment of, or taking possession by, a receiver,
liquidator, assignee, trustee, custodian, sequestrator (or other similar official) for Maker or for any substantial part of its property,
or the making by it of any assignment for the benefit of creditors, or the failure of Maker generally to pay its debts as such debts become
due, or the taking of corporate action by Maker in furtherance of any of the foregoing.
Attn:
Jonathan P. Myers
Notice shall
be deemed given on the earlier of (i) actual receipt by the receiving party, (ii) the date shown on a facsimile transmission confirmation,
(iii) the date reflected on a signed delivery receipt, or (iv) two (2) Business Days following tender of delivery or dispatch by express
mail or delivery service.
IN WITNESS WHEREOF,
Maker,intending to be legally bound hereby, has caused this Note to be duly executed on the day and year first above written.
THIS NOTE HAS NOT
BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”). THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT
ONLY AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF REGISTRATION OF THE RESALE THEREOF UNDER THE SECURITIES ACT OR AN
OPINION OF COUNSEL REASONABLY SATISFACTORY IN FORM, SCOPE AND SUBSTANCE TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED.
Attn:
Jonathan P. Myers
Notice shall
be deemed given on the earlier of (i) actual receipt by the receiving party, (ii) the date shown on a facsimile transmission confirmation,
(iii) the date reflected on a signed delivery receipt, or (iv) two (2) Business Days following tender of delivery or dispatch by express
mail or delivery service.
IN WITNESS WHEREOF, Maker, intending
to be legally bound hereby, has caused this Note to be duly executed on the day and year first above written.
THIS NOTE HAS NOT BEEN REGISTERED
UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”). THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT ONLY AND MAY
NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF REGISTRATION OF THE RESALE THEREOF UNDER THE SECURITIES ACT OR AN OPINION OF COUNSEL
REASONABLY SATISFACTORY IN FORM, SCOPE AND SUBSTANCE TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED.
Attn: Jonathan P. Myers
Notice shall be deemed
given on the earlier of (i) actual receipt by the receiving party, (ii) the date shown on a facsimile transmission confirmation, (iii)
the date reflected on a signed delivery receipt, or (iv) two (2) Business Days following tender of delivery or dispatch by express mail
or delivery service.
IN WITNESS WHEREOF, Maker, intending
to be legally bound hereby, has caused this Note to be duly executed on the day and year first above written.
THIS NOTE HAS
NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”). THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT
ONLY AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF REGISTRATION OF THE RESALE THEREOF UNDER THE SECURITIES ACT OR AN
OPINION OF COUNSEL REASONABLY SATISFACTORY IN FORM, SCOPE AND SUBSTANCE TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED.
Attn:
Jonathan P. Myers
Notice shall
be deemed given on the earlier of (i) actual receipt by the receiving party, (ii) the date shown on a facsimile transmission confirmation,
(iii) the date reflected on a signed delivery receipt, or (iv) two (2) Business Days following tender of delivery or dispatch by express
mail or delivery service.
IN WITNESS WHEREOF, Maker, intending
to be legally bound hereby, has caused this Note to be duly executed on the day and year first above written.
THIS NOTE HAS NOT BEEN REGISTERED
UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”). THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT ONLY AND MAY
NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF REGISTRATION OF THE RESALE THEREOF UNDER THE SECURITIES ACT OR AN OPINION OF COUNSEL
REASONABLY SATISFACTORY IN FORM, SCOPE AND SUBSTANCE TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED.
Attn: Jonathan P. Myers
Notice shall be deemed
given on the earlier of (i) actual receipt by the receiving party, (ii) the date shown on a facsimile transmission confirmation, (iii)
the date reflected on a signed delivery receipt, or (iv) two (2) Business Days following tender of delivery or dispatch by express mail
or delivery service.
IN WITNESS WHEREOF, Maker, intending
to be legally bound hereby, has caused this Note to be duly executed on the day and year first above written.
THIS NOTE HAS NOT BEEN REGISTERED
UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”). THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT ONLY AND MAY
NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF REGISTRATION OF THE RESALE THEREOF UNDER THE SECURITIES ACT OR AN OPINION OF COUNSEL
REASONABLY SATISFACTORY IN FORM, SCOPE AND SUBSTANCE TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED.
Attn: Jonathan P. Myers
Notice shall be deemed
given on the earlier of (i) actual receipt by the receiving party, (ii) the date shown on a facsimile transmission confirmation, (iii)
the date reflected on a signed delivery receipt, or (iv) two (2) Business Days following tender of delivery or dispatch by express mail
or delivery service.
IN WITNESS WHEREOF, Maker, intending
to be legally bound hereby, has caused this Note to be duly executed on the day and year first above written.
THIS NOTE HAS NOT BEEN REGISTERED
UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”). THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT ONLY AND MAY
NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF REGISTRATION OF THE RESALE THEREOF UNDER THE SECURITIES ACT OR AN OPINION OF COUNSEL
REASONABLY SATISFACTORY IN FORM, SCOPE AND SUBSTANCE TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED.
Attn: Jonathan P. Myers
Notice shall be deemed
given on the earlier of (i) actual receipt by the receiving party, (ii) the date shown on a facsimile transmission confirmation, (iii)
the date reflected on a signed delivery receipt, or (iv) two (2) Business Days following tender of delivery or dispatch by express mail
or delivery service.
IN WITNESS WHEREOF, Maker, intending
to be legally bound hereby, has caused this Note to be duly executed on the day and year first above written.
THIS NOTE HAS NOT BEEN REGISTERED
UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”). THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT ONLY AND MAY
NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF REGISTRATION OF THE RESALE THEREOF UNDER THE SECURITIES ACT OR AN OPINION OF COUNSEL
REASONABLY SATISFACTORY IN FORM, SCOPE AND SUBSTANCE TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED.
Attn: Jonathan P. Myers
Notice shall be deemed
given on the earlier of (i) actual receipt by the receiving party, (ii) the date shown on a facsimile transmission confirmation, (iii)
the date reflected on a signed delivery receipt, or (iv) two (2) Business Days following tender of delivery or dispatch by express mail
or delivery service.
IN WITNESS WHEREOF, Maker, intending
to be legally bound hereby, has caused this Note to be duly executed on the day and year first above written.
I, Jonathan P. Myers, certify that:
In connection with the Quarterly
Report of Qomolangma Acquisition Corp. (the “Company”) on Form 10-Q for the quarter ending March 31, 2024, as filed with the
Securities and Exchange Commission on the date hereof (the “Report”), the undersigned Chairman, President and Chief Executive
Officer of the Company, hereby certifies pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act
of 2002, that:
In connection with the Quarterly
Report of Qomolangma Acquisition Corp. (the “Company”) on Form 10-Q for the quarter ending March 31, 2024, as filed with the
Securities and Exchange Commission on the date hereof (the “Report”), the undersigned Chief Financial Officer of the Company,
hereby certifies pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that: